




- (72) NARBAD, Arjan, GB  
(72) RHODES, Michael John Charles, GB  
(72) GASSON, Michael John, GB  
(72) WALTON, Nicholas John, GB  
(71) INSTITUTE OF FOOD RESEARCH, GB  
(51) Int.Cl.<sup>6</sup> C12N 15/52, A23L 2/56, C12N 15/53, C12P 7/42, C12P 7/24,  
A23L 1/22, C12N 1/20, C12N 1/19, C12N 5/10, A23L 1/03,  
C12N 9/02, C12N 9/00, A01H 5/00  
(30) 1996/03/23 (9606187.4) GB  
(54) **PRODUCTION DE VANILLINE**  
(54) **PRODUCTION OF VANILLIN**



(57) Procédé de production de vanilline comprenant les étapes suivantes: (1) on prend un acide trans-férulique ou un sel dudit acide; (2) on expose ledit acide à du transférulate: activité de CoASH ligase (activité enzymatique I), activité de trans-féruloyl SCoA hydratase (activité enzymatique II), et activité de clivage de 4-hydroxy-3-méthoxyphényl-β-hydroxy-propionyl SCoA (HMPHPSCoA) (activité enzymatique III). Les enzymes sont aisément obtenues à partir de

(57) A method of producing vanillin comprising the steps of: (1) providing trans-ferulic acid or a salt thereof; and (2) providing trans-ferulate: CoASH ligase activity (enzyme activity I), trans-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl-β-hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity (enzyme activity III). Conveniently the enzymes are provided by *Pseudomonas fluorescens* Fe3 or a mutant or derivative thereof.





(21) (A1) **2,250,043**  
(86) 1997/03/24  
(87) 1997/10/02

*Pseudomonas fluorescens* Fe3 ou une forme mutante ou dérivée de ces derniers. L'invention concerne également des polypeptides aux activités enzymatiques II et III et des polynucléotides codant ces polypeptides ainsi que leur utilisation dans un procédé de production de vanilline.

Polypeptides with enzymes activities II and III and polynucleotides encoding said polypeptides. Use of said polypeptides or said polynucleotides in a method for producing vanillin.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 9/00, 9/02, 9/88, 15/52, 15/53, 15/60 // C12P 7/24, C12R 1/39	A3	(11) International Publication Number: <b>WO 97/35999</b> (43) International Publication Date: 2 October 1997 (02.10.97)
(21) International Application Number: PCT/GB97/00809 (22) International Filing Date: 24 March 1997 (24.03.97) (30) Priority Data: 9606187.4 23 March 1996 (23.03.96) GB (71) Applicant (for all designated States except US): INSTITUTE OF FOOD RESEARCH [GB/GB]; Norwich Research Park, Colney, Norwich NR4 7UA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): NARBAD, Arjan [GB/GB]; 61 The Avenues, Norwich, Norfolk NR2 3QR (GB). RHODES, Michael, John, Charles [GB/GB]; 35 Brettingham Avenue, Cringleford, Norwich, Norfolk NR4 6XQ (GB). GASSON, Michael, John [GB/GB]; Old Ash Farm, Stone Lane, Bintree, nr East Dereham, Norfolk NR20 5NA (GB). WALTON, Nicholas, John [GB/GB]; 69 City Road, Norwich, Norfolk NR1 3AS (GB). (74) Agent: BASSETT, Richard; Eric Potter Clarkson, St. Mary's Court, St. Mary's Gate, Nottingham NG1 1LE (GB).		(81) Designated States: AU, CA, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 8 January 1998 (08.01.98)

(54) Title: PRODUCTION OF VANILLIN

## (57) Abstract

A method of producing vanillin comprising the steps of: (1) providing *trans*-ferulic acid or a salt thereof; and (2) providing *trans*-ferulate: CoASH ligase activity (enzyme activity I), *trans*-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity (enzyme activity III). Conveniently the enzymes are provided by *Pseudomonas fluorescens* Fe3 or a mutant or derivative thereof. Polypeptides with enzymes activities II and III and polynucleotides encoding said polypeptides. Use of said polypeptides or said polynucleotides in a method for producing vanillin.

Vanillin Pathway in *Pseudomonas fluorescens*, biovar V, strain AN103

## PRODUCTION OF VANILLIN

The present invention relates principally to the production of vanillin (4-hydroxy-3-methoxybenzaldehyde), particularly to the production of vanillin  
5 other than by extraction from the *Vanilla* pod.

Vanillin is an important food and drink flavouring agent and a major flavour component of natural vanilla from the *Vanilla* pod. The use of natural vanilla is limited by its high price. Synthetic vanillin, commonly  
10 derived from sulphite liquors produced during the processing of wood pulp for paper manufacture, is frequently used as a low-cost vanilla substitute. Alternative biological processes for the production of natural vanillin and allied flavourings would have considerable industrial value and utility, most particularly if such processes could facilitate the production of  
15 vanillin and/or allied flavourings directly in a fermented food or beverage.

The mechanism of vanillin biosynthesis in *Vanilla* remains substantially uncharacterised. M.H. Zenk (*Anal. Z. Pflanzenphysiol* **53**, 404-414 (1965)) showed that vanillin was derived from *trans*-ferulate (4-hydroxy-3-methoxy-*trans*-cinnamate) and proposed a mechanism analogous to the  
20 classical  $\beta$ -oxidation of fatty acids, with cleavage of a  $\beta$ -keto thioester to produce acetyl SCoA and vanilloyl SCoA (4-hydroxy-3-methoxybenzoyl SCoA) and subsequent reduction and CoASH release to generate vanillin. C. Funk and P.E. Brodelius (*Plant Physiol.* **94**, 95-101; 102-108 (1990);  
25 **99**, 256-262 (1992)), proposed a different route, in which the 4-hydroxy group of *trans*-ferulate became successively methylated and demethylated during the pathway of vanillin biosynthesis; however, the detailed enzymology was not elucidated. In potato tubers and in the fungus,

*Polyporus hispidus* (C.J. French, C.P. Vance and G.H.N. Towers, *Phytochemistry* **15**, 564-566 (1976)), in cell cultures of *Lithospermum erythrorhizon* (K. Yazaki, L. Heide and M. Tabata, *Phytochemistry* **30**, 2233-2236 (1991)) and in cell cultures of carrot (J.-P. Schnitzler, J. Madlung, A. Rose and H.U. Seitz, *Planta* **188**, 594-600 (1992)), evidence was obtained from *in vitro* studies that the corresponding analogue of vanillin, 4-hydroxybenzaldehyde, was an intermediate in the formation of 4-hydroxybenzoate from 4-coumarate (4-hydroxy-*trans*-cinnamate). There was no requirement for ATP or CoASH, thus apparently ruling out a  $\beta$ -oxidation mechanism. Further studies with cell-free extracts of *Lithospermum erythrorhizon*, however, have in contrast recently established the presence of a  $\beta$ -oxidation route for the conversion of 4-coumarate to 4-hydroxybenzoate (R. Löscher and L. Heide, *Plant Physiol.* **106**, 271-279 (1994)); in this case, the conversion was dependent on ATP,  $Mg^{2+}$  ions and  $NAD^+$  and proceeded via 4-hydroxybenzoyl SCoA, without the intermediate formation of 4-hydroxybenzaldehyde.

In the Gram-negative bacterium, *Pseudomonas acidovorans*, *trans*-ferulate was shown to be catabolised to vanillate and acetate, apparently via vanillin (A. Toms and J.M. Wood, *Biochemistry* **9**, 337-343 (1970)). Although in cell-free extracts  $NAD^+$  was necessary for the oxidation of vanillin to vanillate and for the further oxidation of vanillate to protocatechuate and formate, no mention was made of any other cofactor requirements. Further studies of ferulate utilisation in *Pseudomonas* species have been reported (V. Andreoni and G. Bestetti, *FEMS Microbiology Ecology* **53**, 129-132 (1988); T. Omori, K. Hatakeyama and T. Kodama, *Appl. Microbiol. Biotechnol.* **29**, 497-500 (1988); Z. Huang, L. Dostal and J.P.N. Rosazza, *Appl. Env. Microbiol.* **59**, 2244-2250

(1993)); however, these have not sought to elucidate further the mechanism of the two-carbon cleavage of ferulate. Zenk *et al* (1980) *Anal. Biochem.* **101**, 182-187 describe a procedure for the enzymatic synthesis and isolation of cinnamoyl-CoA thioesters using a bacterial system. In contrast, the enzymology and genetics of the utilisation of simple benzene derivatives, including benzoic acids and phenols, by *Pseudomonas* have been intensively studied (T.K. Kirk, T. Higuchi and H.-M. Chang (eds.), *Lignin biodegradation*", CRC Press, Boca Raton, Fla, USA (1980); D.T. Gibson (ed.), *Microbial degradation of organic compounds*", Marcel Dekker, New York (1984); J.L. Ramos, A. Wasserfallen, K. Rose and K.N. Timmis, *Science* **235**, 593-596 (1987); C.S. Harwood, N.N. Nichols, M.K. Kim, J.L. Ditty and R.E. Parales, *J. Bacteriol.* **176**, 6479-6488 (1994); S. Romerosteiner, R.E. Parales, C.S. Harwood and J.E. Houghton, *J. Bacteriol.* **176**, 5771-5779 (1994); J. Inoue, J.P. Shaw, M. Rekik and S. Harayama, *J. Bacteriol.* **177**, 1196-1201 (1995)).

A survey of potential microbial routes to aromatic aldehydes, including routes (i) from *trans*-cinnamic acids, (ii) from benzoic acids by reduction and (iii) by conversion of aromatic amino acids to phenylpyruvic acids followed by treatment with base, has been presented by J. Casey and R. Dobb (*Enzyme Microb. Technol.* **14**, 739-747 (1992)).

US 5,128,253 describes a method of producing vanillin from ferulic acid by various microorganisms and extracts thereof or enzymes derived therefrom in the presence of a sulphhydryl compound but does not disclose what any of the enzymes involved in the conversion of ferulic acid to

vanillin are. US 5,279,950 is a continuation-in-part application of US 5,128 253 which additionally describes that *Vanilla* calluses can be used in the process.

5 WO 94/13614 describes the production of vanillin from ferulic acid by the action of *Vanilla* root material and makes use of an adsorbent, such as charcoal, to extract vanillin but does not disclose the specific enzymes involved.

10 EP 0 453 368 describes that a culture of *Pycnopus* can convert *trans*-ferulic acid into vanillin but does not disclose the specific enzymes involved.

WO 94/02621 describes the production of vanillin from *trans*-ferulic acid  
15 by the action of a lipoxygenase enzyme. EP 0 405 197 describes the production of vanillin from eugenol/isoeugenol by bacteria from the genera *Serratia*, *Klebsiella* and *Enterobacter* by oxidation.

Vanillin may also be produced from phenolic stilbenes as is mentioned in  
20 Hagedorn & Kaphammer (1994) *Ann. Rev. Microbiol.* **48**, 773-800.

Vanillic acid is also a useful compound as it can be polymerised into oligomers or used as a monomer in the synthesis of polyesters; similarly *p*-hydroxybenzoic acid is also useful for polymer synthesis.

25

A first aspect of the invention provides a method of producing vanillin comprising the steps of

- (1) providing *trans*-ferulic acid or a salt thereof; and
- (2) providing *trans*-ferulate:CoASH ligase activity (enzyme activity I),  
*trans*-feruloyl SCoA hydratase activity (enzyme activity II), and 4-  
hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP  
5 SCoA) cleavage activity (enzyme activity III).

The advantages of the present invention over chemical synthesis or extraction from the *Vanilla* pod include (i) economic advantage over extraction from *Vanilla* pod and freedom from geographical dependence  
10 on *Vanilla* growing areas; (ii) the ability to produce vanillin by a natural process, involving biological catalysts; (iii) the benefits of generating a natural flavour *in situ* in a fermented food or beverage, if the genes are expressed in appropriate food-grade hosts - eg lactic acid bacteria or yeasts; and (iv) the possibility of expanding the range of plants in which  
15 vanillin and related substances might be produced and from which they might be extracted. These and other examples of the methods of the invention are described in more detail below.

We have determined the mechanism of chain-shortening of *trans*-ferulate  
20 (*trans*-ferulic acid) by a strain of *Pseudomonas fluorescens* (named *Ps. fluorescens* biovar. V, strain AN103 and which we have abbreviated at some points to AN103) isolated from soil. Our data indicate clearly that vanillin (4-hydroxy-3-methoxy benzaldehyde) is an intermediate and that the mechanism does not involve  $\beta$ -oxidation. The vanillin pathway of *Ps.*  
25 *fluorescens* biovar. V, strain AN103 is described in Figure 1. *Trans*-ferulic acid (or a salt thereof) is interconverted with *trans*-feruloyl SCoA in the presence of CoASH; *trans*-feruloyl SCoA is interconverted



with 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionyl SCoA (HMPHP SCoA); and HMPHP SCoA is interconverted with vanillin.

For convenience, *trans*-ferulate:CoASH ligase activity is called enzyme activity I, *trans*-feruloyl SCoA hydratase activity is called enzyme activity II; and HMPHP SCoA cleavage activity is called enzyme activity III. The interconversions performed by these enzyme activities is shown in Figure 1.

The method of producing vanillin provided by the invention therefore includes the steps of exposing *trans*-ferulic acid or a salt thereof to enzyme activity I and forming a product, exposing the said product of enzyme activity I to enzyme activity II to form a product and exposing the said product of enzyme activity II to enzyme activity III to form a product.

*Trans*-ferulic acid or a salt thereof may be provided directly, for example by supplying pre-prepared *trans*-ferulic acid or a salt thereof, or it may be provided indirectly, for example by supplying a precursor of *trans*-ferulic acid or a precursor of a salt of *trans*-ferulic acid and means to convert the said precursor into *trans*-ferulic acid or a salt thereof. As is described in more detail below, it is convenient if the precursor is an ester of *trans*-ferulic acid and the means to convert said ester is a suitable esterase.

By "providing *trans*-ferulate:CoASH ligase activity (enzyme activity I), *trans*-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity (enzyme activity III)" we include the provision of the enzyme activities in any suitable form to effect the said production of

vanillin. For example, as is discussed in more detail below, the method of the invention specifically includes, but is not limited to, the provision of the enzyme activities (a) by intact or permeabilised *Ps. fluorescens* biovar. V, strain AN103 or a mutant thereof, (b) at least one of enzyme activities II or III of which is in a form substantially free of cellular material, (c) by intact or permeabilised cells in culture, particularly microorganisms, which have been genetically modified to contain genes which encode enzyme activities II or III (for example, food grade microorganisms such as lactic acid bacteria and brewing yeast), and (d) by plants which have been genetically modified to contain genes which encode said enzyme activities.

It is preferred if means for converting vanillin to a non-vanillin product is absent or reduced. Of course, the enzyme activity III is not such a means. Conveniently, these enzyme activities are provided by the soil bacterium *Pseudomonas fluorescens* biovar. V, strain AN103 the said bacterium being that deposited under the Budapest Treaty at the National Collection of Industrial and Marine Bacteria Limited, AURIS Business Centre, 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof. By "mutant or variant thereof" we include any mutant or variant of the said bacterium provided that the bacterium retains the said enzyme activities whether or not at the same levels. It will be appreciated that the said enzyme activities can be retained even if the genes encoding said enzymes are mutated. For example, mutants which constitutively express (as opposed to conditionally or inducibly express) the said enzyme activities are particularly useful mutants of *Ps. fluorescens* biovar. V, strain AN103, as are variants in which one or more of the enzymes with the said activities

exhibit more favourable kinetic characteristics (for example, an increased turnover number or a decreased  $K_m$ ).

When *Ps. fluorescens* biovar. V, strain AN103 is growing on  
5 *trans*-ferulate it will derive maximum benefit if vanillin is catabolised further in order to provide more energy. However, in order to maximise the production of vanillin by *Ps. fluorescens* biovar. V, strain AN103 it is preferred that the means for converting vanillin to a non-vanillin product is absent or reduced. We have found that in *Ps. fluorescens*  
10 biovar. V, strain AN103 vanillin is converted to vanillic acid or a salt thereof by vanillin:NAD<sup>+</sup> oxidoreductase. It is preferred if a mutant of *Ps. fluorescens* biovar. V, strain AN103 wherein the vanillin:NAD<sup>+</sup> oxidoreductase activity is absent or reduced is used in the method. Such a mutant can be made using a gene replacement strategy with a disrupted  
15 vanillin:NAD oxidoreductase gene, or a sequence of DNA from which this gene has been deleted. Gene replacement is well known in the art of bacterial genetics. Alternatively, isolation of such a mutant may be achieved by classical chemical mutagenesis, selecting on the basis of inability to grow on vanillin.

20

It will be appreciated that there are other means for converting vanillin to a non-vanillin product and it is preferred if these are absent or reduced in the method.

25 Although *Ps. fluorescens* biovar. V, strain AN103 or mutants or variants thereof themselves are useful in the method of the invention as whole cells or permeabilised or immobilised cells, it is preferred if the enzyme activities I, II and III are provided by an intact-cell-free system of *Ps.*

*fluorescens* biovar. V, strain AN103 or a mutant or variant thereof. Suitable systems and extracts may be used by methods well known in the art, for example by French pressure cell or sonication followed by centrifugation. Alternatively, whole cells may be permeabilised using  
5 methods well known in the art, for example using detergents such as dimethyl sulphoxide (DMSO).

Using such an intact-cell-free system allows the necessary substrates and any cofactors to reach readily the relevant enzymes and for the products  
10 to be released readily into the reaction medium if this is necessary for further reaction; however as discussed below, at least some of the enzymes of the invention may be involved in substrate (metabolic) channelling.

15 We have found that none of the enzyme activities I, II and III from *Ps. fluorescens* biovar. V, strain AN103 is dependent on NAD<sup>+</sup> whereas enzyme activity IV from *Ps. fluorescens* (vanillin:NAD<sup>+</sup> oxido-reductase) requires NAD<sup>+</sup>.

20 Thus, a preferred way of reducing means for converting vanillin to a non-vanillin product in an intact-cell-free system of *Ps. fluorescens* biovar. V, strain AN103 (or in a cell-permeabilised system of *Ps. fluorescens* biovar. V, strain AN103) is to omit NAD<sup>+</sup> from the reaction system. Any exogenous NAD<sup>+</sup> is readily and rapidly depleted by the presence of  
25 *trans*-ferulate in the system.

For the microorganisms of the present invention which can be used in the method of vanillin production, including *Ps. fluorescens* biovar. V, strain

AN103, at least three main types of bioreactor may be used for the biotransformation reactions: the batch tank, the packed bed and the continuous-flow stirred tank; their applications and characteristics have been reviewed (M.D. Lilly in "Recent Advances in Biotechnology", eds. F. Vardar-Sukan and S.S. Sukan, Kluwer Academic Publishers, Dordrecht, 1992, pp 47-68 and *loc. cit.*).

As is described in more detail below, enzyme activities II and III are available free from other enzyme activities, for example directly or indirectly from *Ps. fluorescens* biovar. V, strain AN103 and from other organisms or cells which have been genetically modified to express genes encoding the said enzyme activities.

It will be appreciated that other microorganisms will be found which will be useful in the methods of the invention, for example, by screening. Such microorganisms and methods of screening and methods of use form part of the invention. The method of screening for other microorganisms possessing activities I, II and III is essentially that already described in the Materials and Methods section in the Examples for the isolation of AN 103. The important aspect is isolation from an environment rich in *trans*-ferulate or related compounds (eg 4-*trans*-coumarate, *trans*-caffeate [3,4-dihydroxy-*trans*-cinnamate] which, as described below, may also be substrates for enzyme activity I) and selection for growth on *trans*-ferulate (preferably) as sole carbon source. In practice, preferred sources are those in which plant-derived materials are being degraded; in addition to soil or compost, this would include the outflow or residues from factories or other installations processing such materials - eg sugar-beet factories, cocoa fermentation heaps etc - and the contents of the gastro-intestinal

tract, particularly of ruminants and other herbivores. It is possible that anaerobes might be found possessing these activities and due account can readily be taken of this in the isolation procedure. *A priori*, isolation of organisms with these activities might also be possible from marine  
5 environments.

Genera in which further microorganisms useful in the invention will be found include *Pseudomonas*, *Arthrobacter*, *Alcaligenes*, *Acinetobacter*, *Flavobacterium*, *Agrobacterium*, *Rhizobium*, *Streptomyces*,  
10 *Saccharomyces*, *Penicillium* and *Aspergillus*.

An alternative or additional approach is to use any one of the *Pseudomonas* genes encoding enzyme activities II or III described herein or redundant sequences designed from the *Pseudomonas* enzyme amino-  
15 acid sequences in DNA probes or PCR amplification strategies to find related genes in other organisms. As is made more clear below, enzymes and nucleotide sequences which are functionally equivalent to those of isolated from AN103 but which differ in sequence form part of the invention.

20

Our studies indicate that the enzyme which interconverts *trans*-ferulate and *trans*-feruloyl SCoA in *Ps. fluorescens* biovar. V, strain AN103 uses Coenzyme A (CoASH), ATP and  $Mg^{2+}$  or other functionally equivalent cofactors. Thus, it is preferred that the method further comprises the step  
25 of (3) providing any one of the cofactors CoASH, ATP or  $Mg^{2+}$  or other functionally equivalent cofactors. ATP is adenosine triphosphate. It is well known that other functionally equivalent cofactors can substitute in some cases for CoASH, ATP or  $Mg^{2+}$ . For example  $Mn^{2+}$  may be used

in place of  $Mg^{2+}$  and derivatives or analogues of ATP, preferably with a hydrolysable  $\gamma$ -phosphate, may be used in place of ATP.

We have also determined that, at least when the enzyme activity I is provided by the *Pseudomonas* AN103 enzyme which interconverts *trans*-ferulate and *trans*-feruloyl SCoA and which enzyme uses ATP and Coenzyme ASH, it is convenient to include a system wherein either one, or both, of the cofactors Coenzyme ASH and ATP is recycled. The following ATP generation and CoASH recycling systems are preferred.

10

ATP generation:-

- (i)  $\text{trans-Ferulate} + \text{CoASH} + \text{ATP} + \text{H}_2\text{O} \rightarrow \text{Vanillin} + \text{Acetyl SCoA} + \text{AMP} + \text{PPi}$  (overall reaction catalysed by *Ps. fluorescens* biovar. V, strain AN103 extract)
- (ii)  $\text{AMP} + \text{ATP} \rightleftharpoons 2 \text{ADP}$  (adenylate kinase)
- (iii)  $\text{Acetyl } \sim \text{P} + \text{ADP} \rightleftharpoons \text{Acetate} + \text{ATP}$  (acetate kinase)
- (iv) Sum:  $\text{trans-Ferulate} + \text{CoASH} + 2 \text{Acetyl } \sim \text{P} + \text{H}_2\text{O} \rightarrow \text{Vanillin} + \text{Acetyl SCoA} + 2 \text{Acetate} + \text{PPi}$


20

CoASH recycling is achievable using commercially-available citrate synthase (EC 4.1.3.7) and citrate lyase (EC 4.1.3.6), viz:-

- (v)  $\text{Acetyl SCoA} + \text{Oxaloacetate} + \text{H}_2\text{O} \rightleftharpoons \text{Citrate} + \text{CoASH}$  (citrate synthase)
- (vi)  $\text{Citrate} \rightleftharpoons \text{Oxaloacetate} + \text{Acetate}$  (citrate lyase)

25

Overall sum, (iv)-(vi):



The acetyl  $\sim$  P used in the overall process, (vii), would not itself be  
 5 generated by enzymic means; however, none of its atoms would appear in the vanillin product.

Acetyl phosphate is commercially available or can be synthesised using the method described by Stadtman (1957) *Meth. Enzymol.* 3, 228-231.

10

The reagents are commercially available from, for example Sigma Chemical Co, Fancy Road, Poole, Dorset, UK. Citrate lyase is typically from *Enterobacter aerogenes*; citrate synthase is typically from chicken heart, pigeon breast muscle or porcine heart.

15

Thus, it is preferred if coenzyme ASH is recycled using the enzymes citrate synthase and citrate lyase; and it is preferred if the ATP is generated using the enzymes adenylate kinase (EC 2.7.4.3) and acetate kinase (EC 2.7.2.1).

20

The co-factor recycling system is particularly preferred when using an intact-cell-free system.

*Trans*-ferulic acid or a salt thereof is readily available from plant material.

25

Suitably, *trans*-ferulic acid or a salt thereof is released from the plant material by the action of ferulic acid esterase. Thus, in a particularly preferred embodiment of the invention the *trans*-ferulic acid or salt thereof is provided by the action of ferulic acid esterase on plant material.



*Trans*-ferulic acid and *trans*-4-coumaric acid can together represent up to 1.5% by weight of the cell walls of temperate grasses (R.D. Hartley and E.C. Jones, *Phytochemistry* **16**, 1531-1534 (1977)). *Trans*-ferulic acid is reported to comprise 0.5% (w/w) of wheat bran (M. C. Ralet, J.-F. Thibault and G. Della Valle, *J. Cereal Sci.* **11**, 249-259 (1990)), 3.1% of maize bran (L. Saulnier, C. Marot, E. Chanliaud and J.-F. Thibault, *Carbohydr. Polym.* **26**, 279-287 (1995)) and 0.8% of sugar beet pulp (V. Micard, G.M.G.C. Renard and J.-F. Thibault, *Lebensm.-Wiss. u-Technol.* **27**, 59-66 (1994)). These materials are amongst the preferred sources of *trans*-ferulic acid. Since *trans*-ferulic acid is present esterified with cell-wall polysaccharides, hydrolysis is essential. Alkaline or acid hydrolysis is possible, but enzymic hydrolysis is preferred. Typically, the initial step is the partial enzymic hydrolysis of carbohydrates (arabinans, xylans, rhamnogalacturanans) to which *trans*-ferulate is linked, followed by the release of *trans*-ferulate from the oligosaccharide fragments by *trans*-ferulic acid esterase activity. In practice, both steps may occur simultaneously in the reaction mixture. Descriptions of representative laboratory-scale processes are available in the literature (for example see L.P. Christov and B.A. Prior, *Enzyme Microb. Technol.* **15**, 460-475 (1993)); C.B. Faulds and G. Williamson, *Appl. Microbiol. Biotechnol.* **43**, 1082-1087 (1995); C.B. Faulds, P.A. Kroon, L. Saulnier, J.-F. Thibault and G. Williamson, *Carbohydrate Polymers* **27**, 187-190 (1995)). Phenolic acid-releasing enzymes have been reported from a number of microorganisms, including *Streptomyces olivochromogenes* (C.B. Faulds and G. Williamson, *J. Gen. Microbiol.* **137**, 2337-2345 (1991)), *Penicillium pinophilum* (A. Castanares, S.I. McCrae and T.M. Wood, *Enzyme Microb. Technol.* **14**, 875-884 (1992)), *Neocallimastix* spp. (W.S. Borneman, R.D. Hartley, W.H. Morrison, D.E. Akin and L.G.

Ljungdahl, *Appl. Microbiol. Biotechnol.* **33**, 345-351 (1990)), *Schizophyllum commune* (R.C. MacKenzie and D. Bilous, *Appl. Envir. Microbiol.* **54**, 1170-1173 (1988)) and *Aspergillus* spp. (M. Tenkanen, J. Schuseil, J. Puls and K. Poutanen, *J. Biotechnol.* **18**, 69-84 (1991); C.B. Faulds and G. Williamson, *Microbiology* **140**, 779-787 (1994)). A *trans*-ferulic acid esterase (XYLD) has been characterised from *Pseudomonas fluorescens* subsp. *cellulosa*, together with an arabinofuranosidase (XYLC) and an endoxylanase (XYLB; L.M.A. Ferreira, T.M. Wood, G. Williamson, C.B. Faulds, G.P. Hazlewood and H.J. Gilbert, *Biochem. J.* **294**, 349-355 (1993)). The genes for all three enzymes have been isolated (G.P. Hazlewood and H.J. Gilbert, in "Xylans and Xylanases", eds. J. Visser, G. Beldman, M.A. Kusters-van Someren and A.G.J. Voragen, Elsevier, Amsterdam, pp 259-273 (1992)). All of these references are incorporated herein by reference.

15

Thus, advantageously the *trans*-ferulic acid or a salt thereof may be provided by the action of *trans*-ferulic acid esterase on said ester. More particularly, it is advantageous to introduce a gene encoding said esterase into a host cell or organism which is being used in the methods of the invention. Thus, it is convenient to introduce a *trans*-ferulic acid esterase gene, such as the aforementioned XYLD gene, into a plant which is being used in the methods of the invention.

Although, as described above, the method may be performed using enzyme activities I, II and III which are provided by *Ps. fluorescens* biovar. V, strain AN103 or mutants or variants thereof themselves, or intact-cell-free extracts thereof, it is preferred if at least one of the enzyme activities II and III is provided by a substantially purified enzyme.

Substantially purified enzymes with enzyme activities II and III are described below.

In a particularly preferred embodiment of the invention the method of the first aspect of the invention further comprises providing a compound, in addition to *trans*-ferulic acid or a salt thereof, which may be converted by any one of enzyme activities I, II or III into a desirable product. Suitably said compound is converted by any one or more of said enzyme activities into a product which is found in, and preferably contributes to the taste or aroma of, vanilla as extracted from *Vanilla* pod.

Vanilla as extracted from *Vanilla* pod contains vanillin as a major component but also smaller quantities of desirable components such as *p*-hydroxybenzoic acid, *p*-hydroxybenzaldehyde and vanillic acid. Typically these components, and vanillin, are present as glucosides in green vanilla pods as well as in the free form. However, upon hydrolysis or fermentation of the green pods or of hydrolysis of the fermented pods, most of the components are present in the free form.

Thus, it is particularly preferred if said compound is any one of *trans*-4-coumaric acid or a salt thereof, *trans*-4-coumaroyl SCoA, *trans*-caffeic acid or a salt thereof, *trans*-caffeoyl SCoA, or 3,4-methylenedioxy-*trans*-cinnamic acid or a salt thereof. By the action of one or more of enzyme activities I, II or III *trans*-4-coumaric acid or a salt thereof and *trans*-4-coumaroyl SCoA are converted to *p*-hydroxybenzaldehyde; *trans*-caffeic acid or a salt thereof and *trans*-caffeoyl SCoA are converted to 3,4-dihydroxybenzaldehyde; and 3,4-methylenedioxy-*trans*-cinnamic acid or a salt thereof is converted to heliotropin.

It is preferred if the compound is *trans*-4-coumaric acid or a salt thereof or *trans*-4-coumaroyl SCoA and that the desirable product is 4-hydroxybenzaldehyde which is a significant component of natural *Vanilla* extract.

5

The enzyme activities I, II and III from *Ps. fluorescens* biovar V, strain AN103 are able to use *trans*-caffeate and *trans*-4-coumarate, (and, as appropriate, the products of their reaction with enzyme activity I) with reasonable efficiency whereas cinnamate and 3,4-methylenedioxy-*trans*-  
10 cinnamate, although may be used as substrates, are poor substrates of the AN103 enzymes.

Thus, the method of the first aspect of the invention is suited to make vanilla flavourings and aromas which more closely resemble the vanilla  
15 from *Vanilla* pod.

The method of the first aspect of the invention may, in certain circumstances, also be performed using the host cells and genetically modified cells and organisms as described below in more detail.

20

A second aspect of the invention provides a method of producing vanillic acid, or a salt thereof, comprising the steps of

- (1) providing *trans*-ferulic acid or a salt thereof;
- 25 (2) providing *trans*-ferulate:CoASH ligase activity, *trans*-feruloyl SCoA hydratase activity, and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity; and
- (3) providing an activity that interconverts vanillin and vanillic acid.

For convenience, the activity that interconverts vanillin and vanillic acid is called enzyme activity IV. Conveniently the activity is provided by vanillin:NAD<sup>+</sup> oxidoreductase (vanillin dehydrogenase). Suitably, this activity is provided by *Ps. fluorescens* biovar. V, strain AN103. Methods  
5 of converting vanillin to vanillic acid or a salt thereof are also known in the art, for example Perestelo *et al* (1989) *App. Environ. Microbiol.* **55**, 1660-1662 describes the production of vanillic acid from vanillin by resting cells of *Serratia marcescens* and Pomelto & Crawford (1983) *App. Environ. Microbiol.* **45**, 1582-1585 describe whole-cell bioconversion of  
10 vanillin to vanillic acid by *Streptomyces viridosporus*.

The method of producing vanillic acid provided by the invention therefore includes the steps of exposing *trans*-ferulic acid or a salt thereof to enzyme activity I and forming a product, exposing the said product of enzyme  
15 activity I to enzyme activity II to form a product, exposing the said product of enzyme activity II to enzyme activity III to form a product, and exposing the said product of enzyme activity III to enzyme activity IV to form a product.

20 It will be appreciated that vanillic acid can be made by the same means as vanillin is made in the method of the first aspect of the invention provided, of course, that enzyme activity IV is supplied.

A further preferred embodiment of the first aspect of the invention  
25 comprises the further step of separating vanillin from the other reaction components.

Vanillin, and other aromatic aldehydes, are, for example, recoverable by extraction with solvent, including supercritical carbon dioxide, and by organophilic pervaporation, using membranes constructed of hydrophobic polymers (G. Bengston and K.W. Bodekker, in "Bioflavour 95", eds. P. Étievant and P. Schreier, INRA, Paris, pp 393-403 (1995); S.M. Zhang and E. Drioli, *Separ. Sci. Technol.* 8, 1-31 (1994)); pervaporation technology has been applied, for example, to the recovery of flavour compounds of wine (N. Rajagopalan and M. Cheryan, *J. Membrane Sci.* 104, 243-250 (1995)). Solid-phase extraction, followed by desorption with solvent, is also possible, though less preferred.

However, in some circumstances, particularly where minor reaction products are present which are similar to compounds present in the vanilla isolated from *Vanilla* pod, vanillin is not isolated.

15

A further preferred embodiment of the second aspect of the invention comprises the further step of separating vanillic acid or a salt thereof from the other reaction components.

20 Vanillic acid and other carboxylic acids may, for example, be recovered by solid-phase extraction, by solvent extraction under acidic conditions, or by pertraction; for example, L. Boyadzhiev and I. Atanassova (*Process Biochemistry* 29, 237-243 (1994)) describe the recovery of the aromatic amino acid, phenylalanine, by pertraction.

25

A third aspect of the invention provides *Pseudomonas fluorescens* biovar. V, strain AN103 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, AURIS Business

Centre, 23 St Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof. Preferred mutants and variants are the same as those preferred in the first aspect of the invention. A particularly preferred mutant of *Ps. fluorescens* biovar. V, strain AN103 is one which accumulates vanillin when provided with *trans*-ferulic acid or a salt thereof. Conveniently, this is a mutant of *Ps. fluorescens* biovar. V, strain AN103 wherein vanillin:NAD<sup>+</sup> oxidoreductase activity is absent or reduced. Suitably, there is a mutation in the gene encoding vanillin:NAD<sup>+</sup> oxidoreductase such that the enzyme activity is absent or substantially reduced. Such a mutant can be made as described above.

A fourth aspect of the invention provides a polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of *trans*-feruloyl SCoA and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionyl SCoA (HMPHP SCoA). Such a polypeptide has enzyme activity II. Conveniently, the polypeptide comprises *trans*-feruloyl SCoA hydratase; more conveniently the polypeptide comprises *trans*-feruloyl SCoA hydratase from *Ps. fluorescens* biovar. V, strain AN103 or fragments or variants thereof which have at least 1 % of the specific activity of the native enzyme (in relation to *trans*-feruloyl SCoA hydratase activity), preferably at least 10 %, more preferably at least 100 %.

The enzyme activity is readily purified as described in the Examples. Modifications to this procedure may be readily made by the person skilled in the art so that a polypeptide with enzyme activity II can be obtained

from any suitable source making use of the enzyme activity II assay procedure described in the Examples.

It is preferred if the polypeptide of the fourth aspect of the invention  
5 comprises the amino acid sequence.

MetSerThrTyrGluGlyArgTrpLysThrValLysValGluIleGluAspGlyIleAla  
PheValIleLeuAsnArgProGluLysArgAsnAlaMetSerProThrLeuAsnArgGlu  
MetIleAspValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuThr  
10 GlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheArgGluValAsp  
AlaGlyProGluIleLeuGlnGluLysIleArgArgGluAlaSerGlnTrpGlnTrpLys  
LeuLeuArgMetTyrAlaLysProThrIleAlaMetValAsnGlyTrpCysPheGlyGly  
GlyPheSerProLeuValAlaCysAspLeuAlaIleCysAlaAspGluAlaThrPheGly  
LeuSerGluIleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAsp  
15 ThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrPheGlyGlyGln  
LysAlaAlaGluMetGlyLeuValAsnGluSerValProLeuAlaGlnLeuArgGluVal  
ThrIleGluLeuAlaArgAsnLeuLeuGluLysAsnProValValLeuArgAlaAlaLys  
HisGlyPheLysArgCysArgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAla  
LysLeuAspGlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGln  
20 PheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArg (SEQ ID No 2),

or a fragment or variant thereof.

The amino acid sequence is that given in Figure 12 as that encoded by  
25 nucleotides 2872 to 3699.

A fifth aspect of the invention provides a polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the



- interconversion of 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP SCoA) and vanillin. Such a polypeptide has enzyme activity III. Conveniently, the polypeptide comprises HMPHP SCoA cleavage enzyme; more conveniently the polypeptide comprises HMPHP SCoA cleavage enzyme from *Ps. fluorescens* biovar. V, strain AN103 or fragments or variants thereof which have at least 1% of the specific activity of the native enzyme (in relation to HMPHP SCoA cleavage activity), preferably at least 10%, more preferably at least 100%.
- 10 The enzyme activity is readily purified as described in the Examples. Modifications to this procedure may be readily made by the person skilled in the art so that a polypeptide with enzyme activity III can be obtained from any suitable source making use of the enzyme activity III assay procedure described in the Examples.
- 15 It is preferred if the polypeptide of the fifth aspect of the invention comprises the amino acid sequence
- MetSerThrTyrGluGlyArgTrpLysThrValLysValGluIleGluAspGlyIleAla  
 20 PheValIleLeuAsnArgProGluLysArgAsnAlaMetSerProThrLeuAsnArgGlu  
 MetIleAspValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuThr  
 GlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheArgGluValAsp  
 AlaGlyProGluIleLeuGlnGluLysIleArgArgGluAlaSerGlnTrpGlnTrpLys  
 LeuLeuArgMetTyrAlaLysProThrIleAlaMetValAsnGlyTrpCysPheGlyGly  
 25 GlyPheSerProLeuValAlaCysAspLeuAlaIleCysAlaAspGluAlaThrPheGly  
 LeuSerGluIleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAsp  
 ThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrPheGlyGlyGln  
 LysAlaAlaGluMetGlyLeuValAsnGluSerValProLeuAlaGlnLeuArgGluVal

ThrIleGluLeuAlaArgAsnLeuLeuGluLysAsnProValValLeuArgAlaAlaLys  
 HisGlyPheLysArgCysArgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAla  
 LysLeuAspGlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGln  
 PheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArg (SEQ ID No 2),

5

or a fragment or variant thereof.

The amino acid sequence is that given in Figure 12 as that encoded by nucleotides 2872 to 3699.

10

A sixth aspect of the invention provides a polypeptide comprising the amino acid sequence

MetLeuAspValProLeuLeuIleGlyGlyGlnSerCysProAlaArgAspGlyArgThr  
 15 PheGluArgArgAsnProValThrGlyGluLeuValSerArgValAlaAlaAlaThrLeu  
 GluAspAlaAspAlaAlaValAlaAlaAlaGlnGlnAlaPheProAlaTrpAlaAlaLeu  
 AlaProAsnGluArgArgSerArgLeuLeuLysAlaAlaGluGlnLeuGlnAlaArgSer  
 GlyGluPheIleGluAlaAlaGlyGluThrGlyAlaMetAlaAsnTrpTyrGlyPheAsn  
 ValArgLeuAlaAlaAsnMetLeuArgGluAlaAlaSerMetThrThrGlnValAsnGly  
 20 GluValIleProSerAspValProGlySerPheAlaMetAlaLeuArgGlnProCysGly  
 ValValLeuGlyIleAlaProTrpAsnAlaProValIleLeuAlaThrArgAlaIleAla  
 MetProLeuAlaCysGlyAsnThrValValLeuLysAlaSerGluLeuSerProAlaVal  
 HisArgLeuIleGlyGlnValLeuGlnAspAlaGlyLeuGlyAspGlyValValAsnVal  
 IleSerAsnAlaProAlaAspAlaAlaGlnIleValGluArgLeuIleAlaAsnProAla  
 25 ValArgArgValAsnPheThrGlySerThrHisValGlyArgIleValGlyGluLeuSer  
 AlaArgHisLeuLysProAlaLeuLeuGluLeuGlyGlyLysAlaProLeuLeuValLeu  
 AspAspAlaAspLeuGluAlaAlaValGlnAlaAlaAlaPheGlyAlaTyrPheAsnGln  
 GlyGlnIleCysMetSerThrGluArgLeuIleValAspAlaLysValAlaAspAlaPhe

24

ValAlaGlnLeuAlaAlaLysValGluThrLeuArgAlaGlyAspProAlaAspProGlu  
 SerValLeuGlySerLeuValAspAlaSerAlaGlyThrArgIleLysAlaLeuIleAsp  
 AspAlaValAlaLysGlyAlaArgLeuValIleGlyGlyGlnLeuGluGlySerIleLeu  
 GlnProThrLeuLeuAspGlyValAspAlaSerMetArgLeuTyrArgGluGluSerPhe  
 5 GlyProValAlaValValLeuArgGlyGluGlyGluGluAlaLeuLeuGlnLeuAlaAsn  
 AspSerGluPheGlyLeuSerAlaAlaIlePheSerArgAspThrGlyArgAlaLeuAla  
 LeuAlaGlnArgValGluSerGlyIleCysHisIleAsnGlyProThrValHisAspGlu  
 AlaGlnMetProPheGlyGlyValLysSerSerGlyTyrGlySerPheGlyGlyLysAla  
 SerIleGluHisPheThrGlnLeuArgTrpValThrLeuGlnAsnGlyProArgHisTyr  
 10 ProIle

(SEQ ID No 4) or a fragment or variant thereof.

The amino acid sequence is that given in Figure 12 as that encoded by  
 15 nucleotides 3804 to 5249.

As described in detail in the examples, this polypeptide sequence encodes  
 an enzyme with vanillin:NAD<sup>+</sup> oxidoreductase activity from *Ps.*  
*fluorescens* biovar V., strain AN103.

20

By "variants" we include deletions, insertions and substitutions either  
 conservative or non-conservative, where such changes may reduce or  
 enhance the activity, or may not substantially alter the activity. In  
 particular, the seventh aspect of the invention includes the complete  
 25 polypeptide sequence of *Ps. fluorescens* biovar V, strain AN103  
 vanillin:NAD<sup>+</sup> oxidoreductase and this polypeptide itself.

By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such variants may be made using the methods of protein engineering and site-directed mutagenesis as described below and as is well known in the art.

A preferred embodiment of the invention is a polypeptide as defined in the fourth, fifth or sixth of the invention which is substantially pure.

By "substantially pure" we mean that the polypeptide is substantially free of other polypeptides, or other macromolecules, with which it is usually found in nature. Suitably, the polypeptide is substantially free of any other polypeptides or macromolecules. It is preferred if the polypeptide has less than 50% by weight of any other polypeptide, preferably less than 10%, more preferably less than 1%, still more preferably less than 0.1% and most preferably less than 0.01%.

Polypeptides can be purified using methods known in the art. It is preferred if the polypeptide is the product of a recombinant DNA.

A single polypeptide chain may comprise more than one of the enzyme activities (II) *trans*-feruloyl SCoA hydratase activity or (III) HMPHP SCoA cleavage activity.

Our data in the Examples shows that, in the case of *Ps. fluorescens* biovar. V, strain AN103, enzyme activities II and III are found in the same polypeptide chain, the sequence of which is given as the preferred polypeptides of the fifth and sixth aspects of the invention. Thus, when

enzyme activities II and III are provided in any aspect of the invention it is most convenient if they are provided in the same polypeptide chain.

It will be appreciated that, using protein engineering methods or chemical cross-linking it may be possible to produce a single molecule which has enzyme activities II and III. Such a molecule, therefore, forms a further aspect of the invention.

An seventh aspect of the invention provides a polynucleotide encoding a polypeptide as defined in any one of the fourth, fifth or sixth aspects of the invention.

By "polynucleotide" we include RNA and DNA. DNA is preferred.

Thus, this aspect of the invention provides a polynucleotide which encodes any one of a polypeptide which has (II) *trans*-feruloyl SCoA hydratase activity; (III) HMPHP SCoA cleavage activity; (IV) vanillin:NAD<sup>+</sup> oxidoreductase activity; or a polypeptide which has more than one of these activities. Preferably the polynucleotide is derived from *Ps. fluorescens* biovar. V, strain AN103. A preferred polynucleotide comprises all or at least a part of the *Ps. fluorescens* DNA contained within the cosmid clone pFI793 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, AURIS Business Centre, 23 St Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40777, or a fragment or variant thereof.

The isolation of the cosmid clone pFI 793 is described in Example 5; pFI 793 includes DNA which encodes polypeptides which have enzyme

activities II, III and IV. The cosmid clone pFI 793 itself, the genes contained in the *Ps. fluorescens* DNA thereof, and variants thereof form separate aspects of the invention.

- 5 A variant of a polynucleotide includes any insertion, deletion or substitution of the sequence which encodes a fragment or variant of a polypeptide as defined above.

For example, site-directed mutagenesis or other techniques can be  
10 employed to create single or multiple mutations, such as replacements, insertions, deletions, and transpositions, as described in Botstein and Shortle, Strategies and Applications of *In Vitro* Mutagenesis, *Science*, 229: 193-210 (1985), which is incorporated herein by reference. Since such modified polynucleotides can be obtained by the application of known  
15 techniques to the teachings contained herein, such modified polynucleotides are within the scope of the claimed invention.

Moreover, it will be recognised by those skilled in the art that the polynucleotide sequence (or fragments thereof) of the invention can be  
20 used to obtain other DNA sequences that hybridise with it under conditions of high stringency. Such DNA includes any genomic DNA.

Accordingly, the polynucleotide of the invention includes DNA that shows at least 55 per cent, preferably 60 per cent, and most preferably 70 per  
25 cent homology with the polynucleotide sequences identified in the invention, provided that such homologous DNA encodes a protein which is usable in the methods described herein.

DNA-DNA, DNA-RNA and RNA-RNA hybridisation may be performed in aqueous solution containing between 0.1XSSC and 6XSSC and at temperatures of between 55°C and 70°C. It is well known in the art that the higher the temperature or the lower the SSC concentration the more stringent the hybridisation conditions. By high stringency we mean 2XSSC and 65°C. 1XSSC is 0.15M NaCl/0.015M sodium citrate.

"Variants" of the polynucleotide include polynucleotides in which relatively short stretches (for example 20 to 50 nucleotides) have a high degree of homology (at least 50% and preferably at least 90 or 95%) with equivalent stretches of the polynucleotide of the invention even though the overall homology between the two polynucleotides may be much less. This is because important active or binding sites may be shared even when the general architecture of the protein is different.

15

A particularly preferred polynucleotide comprises the nucleotide sequence

ATGAGCACATACGAAGGTCGCTGGAAAACGGTCAAGGTCGAAATCGAAGACGGCATCGCG  
TTTGTTCATCCTCAATCGCCCGGAAAAACGCAACGCGATGAGCCCGACCCTGAACCGCGAG  
20 ATGATCGATGTTCTGGAAACCCTCGAGCAGGACCCTGCCGCCGGTGTGCTGGTGCTGACC  
GGTGCGGGCGAAGCCTGGACCGCAGGCATGGACCTCAAGGAATACTTCCGCGAAGTGGAC  
GCCGGCCCGGAAATCCTCCAGGAAAAAATCCGCCGCGAAGCCTCGCAATGGCAATGGAAA  
CTGCTGCGCATGTACGCCAAGCCGACCATCGCCATGGTCAATGGCTGGTGCTTCGGCGGC  
GGTTTCAGCCCGCTGGTGGCCTGCGACCTGGCGATCTGCGCCGACGAAGCAACCTTCGGT  
25 CTCTCGGAAATCAACTGGGGTATCCCGCCGGGCAACCTGGTGAGCAAGGCCATGGCCGAC  
ACCGTGGGCCACCGCCAGTCGCTCTACTACATCATGACCGGCAAGACCTTCGGTGGGCAG  
AAAGCCGCCGAGATGGGCCTGGTCAACGAAAGCGTGCCCTGGCGCAACTGCGCGAAGTC  
ACCATCGAGCTGGCGCGTAACCTGCTCGAAAAAACCCTGGTGGTGCTGCGTGCCGCCAAA

CACGGTTTCAAACGCTGCCGCGAACTGACCTGGGAGCAGAACGAGGATTACCTGTACGCC  
AAGCTCGATCAGTCGCGTTTGCTGGACACCGAAGGCGGTCGCGAGCAGGGCATGAAGCAATTCC  
TCGACGACAAGAGCATCAAGCCTGGCCTGCAAGCGTATAAACGC (SEQ ID No 1)

- 5 (as given in Figure 12, nucleotides 2872 to 5249) or a fragment or variant thereof.

This polynucleotide encodes HMPHP SCoA cleavage enzyme activity and  
a *trans*-feruloyl SCoA hydratase activity from *Ps. fluorescens* biovar. V,  
10 strain AN103 and encodes the preferred polypeptide of the fifth and sixth  
aspects of the invention.

A further particularly preferred polynucleotide comprises the nucleotide  
sequence

15

ATGCTGGACGTGCCCCCTGCTGATTGGCGGCCAGTCGTGCCCCGCGCGGACGGTCGAACC  
TTCGAGCGCCGCAACCCGGTGACTGGCGAGTTGGTGTGCGGGTTGCCGCCGCCACCCTG  
GAAGATGCCGACGCCCGCTGGCCGCTGCCAGCAAGCGTTTCCCGCGTGGGCCGCGCTG  
GCGCCCAATGAACGGCGCAGCCGTTTGCTCAAGGCCGCCGAACAATTGCAGGCGCGCAGC  
20 GGCGAGTTCATCGAGGCGGCGGGCGAGACCGGCGCCATGGCCAACTGGTACGGGTTCAAC  
GTACGGCTGGCGGCCAACATGCTGCGTGAAGCGGCATCGATGACCACCCAGGTCAATGGT  
GAAGTGATTCCCTCGGACGTTCCTCGGCAGTTTCGCCATGGCCCTGCGCCAGCCCTGTGGC  
GTGGTGCTGGGCATCGCCCCCTGGAACGCCCCGGTGATTCTCGCCACCCGGGCGATTGCC  
ATGCCGCTGGCCTGTGGCAACACCGTGGTGTGAAGGCTTCCGAGCTGAGTCCGGCGGTG  
25 CATCGCTTGATCGGCCAGGTGCTGCAGGACGCCGGCCTGGGCGATGGCGTGGTCAACGTC  
ATCAGTAATGCGCCGGCGGATGCGGCACAGATTGTCGAGCGCCTGATTGCCAACCCGGCC  
GTACGCCGGGTCAATTTACCGGTTTCGACCCACGTCGGGCGCATTTGTCGGCGAGCTCTCG  
GCGGCCACCTCAAACCGGCGTTGCTCGAGCTGGGCGGCAAGGCACCGTTGCTGGTGCTC



GACGATGCCGACCTGGAGGCTGCCGTGCAGGCGGCGGCGTTTGGCGCCTACTTCAACCAG  
GGACAGATCTGTATGTCCACCGAGCGCCTGATTGTTCGATGCCAAGGTGGCCGACGCCTTT  
GTCGCCCAGTTGGCGGCCAAGGTCGAGACCCTGCGCGCCGGTGATCCTGCCGACCCGGAG  
TCGGTGCTCGGTTGCTGGTGGACGCCAGCGCTGGCACGCGGATCAAAGCGTTGATCGAT  
5 GATGCCGTGGCCAAGGGCGCGCGCCTGGTAATCGGCGGGCAACTGGAGGGCAGCATCTTG  
CAGCCGACCCTGCTCGACGGTGTGACGCGAGCATGCGTTTGTACCGGAAGAGTCCTTC  
GGCCCCGGTGGCGGTGGTGTGCGCGGCGAGGGCGAAGAAGCGCTGTTGCAACTGGCCAAC  
GACTCCGAGTTCGGTTTGTGCGCGGCGATTTTCAGTCGTGACACCGGCCGTGCCCTGGCC  
CTGGCCCAGCGGGTCGAATCGGGCATCTGCCACATCAACGGCCCCGACCGTGACGACGAA  
10 GCGCAAATGCCTTTTGGCGGGGTCAAGTCCAGCGGCTACGGCAGTTTTGGCGGCAAGGCA  
TCGATTGAGCATTTCACTCAGTTGCGCTGGGTACCCCTCCAGAATGGTCCACGGCACTAT  
CCGATC

(SEQ ID No 3) (as given in Figure 12, nucleotides 3804 to 5249)

15

or a fragment or variant thereof. This polynucleotide encodes the polypeptide sequence of the sixth aspect of the invention. It is particularly convenient to isolate the whole gene from cosmid clone pFI 793 as deposited under the Budapest Treaty at NCIMB under Accession No  
20 NCIMB 40777.

The polynucleotides of the invention are all readily isolated from pFI 793 by probing with the given sequences or parts thereof, or by other methods known in the art, and the nucleotide sequences can be confirmed by  
25 reference to the deposited cosmid (pFI 793).

It will be appreciated that fragments and variants of the polynucleotides of the invention can readily be made by the person skilled in the art using

standard molecular biological methods such as those described in Sambrook *et al* "Molecular Cloning, a laboratory manual", (1989), (2nd Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. The whole gene and variants and fragments thereof are specifically  
5 included in this aspect of the invention.

It is preferred if the polynucleotide, conveniently DNA, is joined to a nucleic acid vector.

10 DNA constructs of the invention may be purified from the host cell using well known methods.

For example, plasmid vector DNA can be prepared on a large scale from cleaved lysates by banding in a CsCl gradient according to the methods of  
15 Clewell & Helinski (1970) *Biochemistry* 9, 4428-4440 and Clewell (1972) *J. Bacteriol.* 110, 667-676. Plasmid DNA extracted in this way can be freed from CsCl by dialysis against sterile, pyrogen-free buffer through Visking tubing or by size-exclusion chromatography.

20 Alternatively, plasmid DNA may be purified from cleared lysates using ion-exchange chromatography, for example those supplied by Qiagen (Chatsworth, CA, USA). Hydroxyapatite column chromatography may also be used.

25 The DNA is then expressed in a suitable host to produce a polypeptide of the invention. Thus, a DNA encoding a polypeptide of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector,

which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter *et al*, 4, 530,901 issued 23 July 1985 to Weissman, 4,582,800  
5 issued 15 April 1986 to Crowl, 4,677,063 issued 30 June 1987 to Mark *et al*, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura *et al*, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. *et al*, 4,766,075 issued 23 August 1988 to Goeddel *et al*, and 4,810,648 issued 7 March  
10 1989 to Stalker, all of which are incorporated herein by reference.

The DNA encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend  
15 upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression.  
20 If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed  
25 by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic

resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of the invention may then be cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which, if desirable, can then be recovered.

- 10 Many expression systems are known, including bacteria (for example *Escherichia coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells and whole plants, animal cells and insect cells.
- 15 The vectors include a prokaryotic replicon, such as the ColE1 *ori*, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial
- 20 host cell, such as *E. coli*, transformed therewith.

Several promoters are available to direct transcription of bacterial and other heterologous genes in plants. In particular, these include the 35S promoter of cauliflower mosaic virus (CaMV 35S), the ribulose

25 bisphosphate carboxylase small subunit promoter and the *Agrobacterium* T-DNA octopine synthase and manopine synthase promoters. These promoters have been widely used, for example, in conjunction with bacterial genes conferring herbicide resistance (see D.M. Stalker, *ibid.*,

pp 82-104). These promoters do not confer any specificity of gene expression at the organ, tissue or organellar levels, or responsiveness of gene expression to environmental influences such as light.

- 5 A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.

10

Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

- 15 A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.

- 20 An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive expression of the cloned gene.

- 25 Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers

*HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps)

A variety of methods have been developed to operably link DNA to  
5 vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

10

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or *E. coli* DNA  
15 polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

The combination of these activities therefore generates blunt-ended DNA  
20 segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These  
25 DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

- 5 A desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki *et al* (1988) *Science* **239**, 487-491.

10 In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

- 15 The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic and it may be comprised in a multicellular organism such as a plant. Bacterial cells are preferred prokaryotic host cells and typically are a strain of *E. coli* such as, for  
20 example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast and plant cells. Yeast host cells include YPH499, YPH500 and YPH501 which are  
25 generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred plant host cells and plants include those from *Nicotiana* spp., *Solanum tuberosum* (potato), *Brassica* spp. (eg oil seed rape), *Beta*

spp. (eg sugar beet, leaf beet and beetroot), *Capsicum* spp. and *Vanilla* spp.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen *et al* (1972) *Proc. Natl. Acad. Sci. USA* **69**, 2110 and Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman *et al* (1986) *Methods In Yeast Genetics, A Laboratory Manual*, Cold Spring Harbor, NY. The method of Beggs (1978) *Nature* **275**, 104-109 is also useful. With regard to plant cells and whole plants three plant transformation approaches are typically used (J. Draper and R. Scott in D. Grierson (ed.), "Plant Genetic Engineering", Blackie, Glasgow and London, 1991, vol. 1, pp 38-81):

- i) *Agrobacterium*-mediated transformation, using the Ti plasmid of *A. tumefaciens* and the Ri plasmid of *A. rhizogenes* (P. Armitage, R. Walden and J. Draper in J. Draper, R. Scott, P. Armitage and R. Walden (eds.), "Plant Genetic Transformation and Expression - A Laboratory Manual", Blackwell Scientific Publications, Oxford, 1988, pp 1-67; R.J. Draper, R.Scott and J. Hamill *ibid.*, pp 69-160);
- ii) DNA-mediated gene transfer, by polyethylene glycol-stimulated DNA uptake into protoplasts, by electroporation, or by microinjection of protoplasts or plant cells (J. Draper, R. Scott, A. Kumar and G. Dury, *ibid.*, pp 161-198);



iii) transformation using particle bombardment (D. McCabe and P. Christou, *Plant Cell Tiss. Org. Cult.*, **3**, 227-236 (1993); P. Christou, *Plant J.*, **3**, 275-281 (1992)).

- 5 *Agrobacterium*-mediated transformation is generally ineffective for monocotyledonous plants (eg *Vanilla*), for which approaches ii) and iii) are therefore preferred. In all approaches a suitable selection marker, such as kanamycin- or herbicide-resistance, is preferred or alternatively a screenable marker ("reporter") gene, such as  $\beta$ -glucuronidase or luciferase
- 10 (see J. Draper and R. Scott in D. Grierson (ed.), "Plant Genetic Engineering", Blackie, Glasgow and London, 1991, vol. 1 pp 38-81).

Electroporation is also useful for transforming cells and is well known in the art for transforming yeast cell, bacterial cells and plant cells.

15

For example, many bacterial species may be transformed by the methods described in Luchansky *et al* (1988) *Mol. Microbiol.* **2**, 637-646 incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell

20 mixture suspended in 2.5X PEB using 6250V per cm at 25 $\mu$ FD.

Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* **194**, 182.

- 25 Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the

invention. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* **98**, 503 or Berent *et al* (1985) *Biotech.* **3**, 208. Alternatively, the presence of the protein in the  
5 supernatant can be detected using antibodies as described below.

In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression  
10 of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity. Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies.

15 Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium; and also, in the case of plant cells, a plant derived from, and containing, such cells.

20 It is particularly preferred if the host cell comprises a nucleic acid which encodes any one of, or combination of, a polypeptide which, in the presence of appropriate cofactors if any is capable of catalysing the interconversion of *trans*-feruloyl SCoA and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionyl SCoA (HMPHP SCoA) or a  
25 polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of

4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionyl SCoA (HMPHP SCoA) and vanillin.

It will be appreciated that the host cells of the invention or an extract thereof are particularly suited for use in the methods of the invention. It is particularly preferred if the host cell does not contain means for converting vanillin to a non-vanillin product.

It is most preferred if the host cell is a plant cell or is comprised in a whole plant or a bacterial cell or a yeast cell. Preferred bacterial hosts include lactic acid bacteria such as *Lactococcus* spp. and *Lactobacillus* spp. Preferred yeast hosts include *Saccharomyces cerevisiae* and its biovars. It is particularly preferred if the host cell is a food-grade host cell (for example a microorganism which is used or can be used in the food or beverage industry). It is also preferred if the plant is an edible plant.

It will be appreciated that some host cells or host organisms may already contain enzyme activities I, II, III or IV and, in that case, it may be sufficient, in order to use the host cells in the methods of the invention, to introduce into said host cell or host organism one or more polynucleotides which encode enzyme activities II, III or IV which encode those enzyme activities which are deficient in the host cell or host organisms.

25

In the case of plants for use in the methods of the invention, it is preferred that the relevant gene expression is directed to target organs, tissues and subcellular organelles where *trans*-feruloyl SCoA, or other appropriate

substrates (eg 4-*trans*-coumaroyl SCoA or *trans*-caffeoyl SCoA) for the enzymes encoded by the transferred genes, are most readily available. The stage at which thioesterification with CoASH occurs in plants, in relation to the progressive substitution of the phenyl ring which takes place during the conversion from *trans*-cinnamate to *trans*-ferulate, is unclear and may be variable (see R. Whetten and R. Sederoff, *The Plant Cell*, 7, 1001-1013 (1995)). The subcellular localisation or distribution of these intermediates during plant phenylpropanoid metabolism also remains uncertain; it is likely that they are cytosolic, or that some functional organisation of the enzymes which metabolise them occurs. The concept of the metabolic cluster or "metabolon", in which there is a degree of metabolic channelling and free diffusion is restricted, has been proposed and discussed (see R.A. Dixon and N.L. Paiva, *The Plant Cell*, 7, 1085-1097 (1995) and *Loc cit.*).

15

*Trans*-ferulate, 4-*trans*-coumarate and *trans*-caffeate are normal metabolic intermediates. Thus, there may be no requirement to manipulate host plants in order to provide *trans*-feruloyl SCoA. Their concentrations are expected to be influenced in varying degrees by physiological requirements for a wide range of end-products of the phenylpropanoid pathway, including for example lignin, coumarins and flavonoids. There is some evidence that the activity of the first enzyme of the phenylpropanoid pathway, phenylalanine ammonia lyase (PAL: EC 4.3.1.5), can influence the accumulation of end-products of the pathway (N. Bate, J. Orr, W. Ni, A. Meromi, T. Nadler-Hassar, P.W. Doerner, R.A. Dixon, C.J. Lamb and Y. Elkind, *Proc. Natl. Acad. Sci. USA*, 91, 7608-7612 (1994)) so under certain circumstances it is possible to enhance the metabolic effects

25

of the expression of the genes for enzyme activities II and III by increasing the expression of PAL.

It is well known that gene expression in the phenylpropanoid pathway is responsive to a range of environmental and stress factors, including wounding, chemical elicitors of pathogenic origin, and u/v light. The mechanisms regulating these responses are not very well understood, though several transcription factors have been identified (see R.A. Dixon and N.L. Paiva, *The Plant Cell*, 7, 1085-1097 (1995)). However, particularly when these are more fully characterised, they do or will offer opportunities for predictable and inducible control of gene expression, particular to enhance the provision of substrate.

Thus, a further aspect of the invention provides a transgenic plant comprising a polynucleotide according to any of the fourth or fifth aspects of the invention. In other words, the transgenic plant is genetically engineered to encode and, preferably, express any one or more of enzyme activities II or III. It is particularly preferred that, following said genetic engineering the plant is able to produce vanillin from *trans*-feruloyl SCoA. It will be appreciated that, depending on the enzymes present in the host plant, it may be necessary only to provide a gene encoding only a single of said enzyme activities or it may be necessary to provide a gene or genes of any two of said enzyme activities.

Conveniently, the transgenic plant is genetically engineered to encode and, preferably, express enzyme activities II and III. It can be readily seen that the transgenic plants of this aspect of the invention may be used in the methods of producing vanillin of the invention, especially when the plant

provides the enzyme activity that interconverts *trans*-ferulic acid or a salt thereof and *trans*-feruloyl SCoA.

Preferably the plant is a plant which is readily transformed. Preferably  
5 the plant is a plant which is commonly used in agriculture or horticulture and more preferably the plant is an edible plant. Advantageously the plant is a plant in which it is desirable to introduce a vanilla flavour or aroma.

Preferred plants include those selected from *Nicotiana* spp., *Solanum*  
10 *tuberosum*, *Brassica* spp., *Capsicum* spp., *Beta* spp. and *Vanilla* spp.

As is described in more detail below the plant may be eaten or may be processed into a foodstuff or beverage. Thus, conveniently the transgenic plant is processed or prepared so that it is not capable of reproduction or  
15 cultivation, for example the transgenic plant is harvested from the environment in which it was grown.

When vanillin (or the desirable products such as *p*-hydroxybenzaldehyde) is produced in a host cell or organism of the invention, especially if it is  
20 produced in a transgenic plant of the invention, the vanillin or desirable product may initially be present in the form of a glycoside, more particularly, a  $\beta$ -D-glycoside, or, in the case of a carboxylic acid, as esters of  $\beta$ -D-glucose (as occurs in *Vanilla* pod). In this case, it is desirable to release the vanillin (and desirable product) into its uncombined  
25 form, for example by acid- or base-catalysed hydrolysis or by the use of glycosides such as the  $\beta$ -D-glucosidase (emulsin; S. Hestrin, D.S. Feingold and M. Schramm, *Meth. Enzymol.* 1, 231-257 (1955); see also D. Chassagne, C. Bayonore, J. Crouzet and K. Baumes in "Bioflavour

95", eds. P. Étiévant and P. Schreier, INRA, Paris, pages 217-222 (1995).).

In relation to the use of a microorganism such as *Ps. fluorescens* biovar  
5 V, strain AN103 or of a microorganism which has been genetically  
modified to contain enzyme activities II and III (or at least those of these  
activities that it does not normally have), it is preferred that said  
microorganism is provided with *trans*-feruloyl SCoA or a means to  
provide said CoA thioester from *trans*-ferulic acid or a salt thereof at least  
10 in its culture medium.

Thus, it can be seen from all of the foregoing description that the  
invention includes biochemical and fermentative processes for producing  
vanillin and vanillic acid, recombinant or transgenic plants and the use of  
15 the said plants in a method of making vanillin or vanillic acid.

Typically, in a biochemical process the strain of *Pseudomonas* (eg *Ps. fluorescens* biovar. V, strain AN103) provides an enzyme system for the  
biotransformation of plant derived *trans*-ferulic acid to vanillin and/or  
20 related compounds. Enzyme preparations, whole cells of *Pseudomonas* or  
a heterologous host organism expressing appropriate *Pseudomonas* genes  
may be used for this. A variety of mutants of *Pseudomonas* and various  
additional enzyme preparations, co-factors or co-factor regenerating  
systems may be used. The *Pseudomonas* enzymes might be overexpressed  
25 in a heterologous host before being extracted and used in a  
biotransformation.

Alternatively, but suitably, some form of fermentation process may be used which involves the *Pseudomonas* strain or an appropriate derived mutant or a heterologous host organism in which the genes for biotransformation are expressed. The chosen microorganism is typically  
5 grown on a ferulate-rich substrate or a substrate comprising *trans*-feruloyl SCoA. This could generate a vanillin production process.

In addition the invention includes recombinant microorganisms (eg lactic acid bacteria) which are modified to contain genes encoding enzyme  
10 activities II and III. For example, lactic acid bacteria modified according to the invention may be used to produce vanilla-flavoured yoghurt provided that they are supplied with *trans*-feruloyl SCoA.

Advantageously, genes for vanillin production (such as those encoding  
15 enzyme activities II and III) are expressed in a variety of plant species such that vanillin accumulates in an appropriate tissue. In this case a new crop plant may be cultivated and vanillin would be extracted. Thus, a sugar beet plant may be made according to the invention in which the beet was rich in vanillin. In addition the development of a novel plant cultivars  
20 for direct consumption (eg vanilla-flavoured capsicum), or even for their desirable aroma properties, included in the invention.

The polypeptides of the invention, or the genes which encode them, may be used either individually or in combination (whether as substantially  
25 isolated polypeptides, or in cell-free extracts or as host cells or organisms which encode and, preferably, express said polypeptides) to convert a compound into a desirable product. Certain compounds and desirable products have been described above. However, the invention also



includes the production of any other desirable product, such as a flavour or aroma, from substrates related to *trans*-ferulate and other known substrates of the polypeptides (enzymes) of the invention. Thus, the polypeptides or genes of the invention, either individually or in  
5 combination, may be used in processes for converting, for example, synthetic substrates of the said polypeptides (enzymes) into novel flavours and aromas or they may be used to modify the chemical profile of known flavours or aromas.

10 Similarly, it will be appreciated that certain desirable products can be made by the further action of enzyme activity IV upon certain compounds, particularly those produced by enzyme activities I, II and III. For example, enzymes activities I, II and III may be used to convert *trans*-4-coumaric acid or *trans*-4-coumaroyl SCoA to *p*-hydroxybenzaldehyde and  
15 enzyme activity IV may then be used to convert *p*-hydroxybenzaldehyde to *p*-hydroxy-benzoic acid. Thus, the invention includes a method of producing *p*-hydroxy-benzoic acid using at least one of enzyme activities I, II, III and IV and advantageously using all of them.

20 A further aspect of the invention provides a food or beverage comprising a host cell comprising a polynucleotide of the invention, or an extract of said host cell. The host cells comprising one or more polynucleotides of the invention, especially those such host cells which produce vanillin by virtue of the presence of said polynucleotide or polynucleotides, may be  
25 used in the production of food or beverages. In particular, as discussed above, lactic acid bacteria which produce vanillin by the methods of the invention may be used in the production of cheese, yogurt and related products including milk drinks. Similarly, yeasts which produce vanillin

by the methods of the invention may be used in the production of food and beverages such as bread and beer. Extracts of said host cells may also be used in the food or beverage industry.

- 5 A still further aspect of the invention provides a food or beverage comprising a transgenic plant comprising a polynucleotide of the invention, or a part or extract of said transgenic plant. The transgenic plant comprising one or more polynucleotides of the invention, especially those such transgenic plants which produce vanillin by virtue of the  
10 presence of said polynucleotide or polynucleotides, may constitute the food itself or they may be processed to form the food or beverage. For example, a tuber of a transgenic potato of the invention constitutes a food of this aspect of the invention. Alternatively, said transgenic potato may be processed into another foodstuff which is, nevertheless, a food of this  
15 aspect of the invention.

Still further aspects of the invention provide use of *Pseudomonas fluorescens* biovar. V, strain AN103 or a mutant or derivative thereof in a method for producing vanillin, or vanillic acid or salt thereof; use of a  
20 polypeptide of the invention in a method for producing vanillin, or vanillic acid or salt thereof; use of a polynucleotide of the invention in a method for producing vanillin, or vanillic acid or salt thereof; and use of a host cell of the invention in a method for producing vanillin or vanillic acid or a salt thereof.

25

As is clear from the foregoing the invention also includes a method of producing vanillin or vanillic acid, or other related products, the method comprising providing *trans*-feruloyl SCoA (or any other suitable CoASH

thioester which can be acted upon by enzyme activity II) and providing enzyme activity II, enzyme activity III and, in the case of vanillic acid production or another related product, enzyme activity IV. *Trans*-feruloyl SCoA is obtainable by the method described in Example 2 or it may be  
5 obtained using the methods of Zenk *et al* (1980) *Anal. Biochem.* **101**, 182-187, incorporated herein by reference. Other CoASH thioesters which may be substrates for enzyme II are also described in Zenk *et al*.

The preferred method steps and organisms for use in the methods, and the  
10 foods and beverages of the earlier aspects of the invention are also preferred in this method of the invention to the extent that they are compatible with this method, and the organisms used in this method.

As is discussed above, *trans*-feruloyl SCoA (and related CoASH thioesters  
15 such as 4-*trans*-coumaroyl SCoA and *trans*-caffeoyl SCoA) are normal metabolic intermediates in plants. Thus, a transgenic plant which comprises a polynucleotide or polynucleotides which encode, and preferably express, enzyme activities II and III in a location in the plant which contains *trans*-feruloyl SCoA or other suitable CoASH thioester is  
20 particularly suited for the purposes of this aspect of the invention. As is described above, such transgenic plants and products derived therefrom form part of the invention.

The invention will now be described in more detail with reference to the  
25 following Examples and Figures wherein:

Figure 1 describes the vanillin pathway in *Pseudomonas fluorescens* biovar. V, strain AN103. HMPHP SCoA is 4-hydroxy-3-methoxy-

phenyl- $\beta$ -hydroxypropionyl SCoA. I is an enzyme that catalyses the interconversion of *trans*-ferulic acid and *trans*-feruloyl SCoA; II is an enzyme that catalyses the interconversion of *trans*-feruloyl SCoA and HMPHP SCoA; III is an enzyme that catalyses the interconversion of  
5 HMPHP SCoA and vanillin; and IV is an enzyme that catalyses the interconversion of vanillin and vanillic acid.

Figure 2 illustrates the growth of strain AN103 following transfer to MM medium containing 10 mM vanillate (V), 10 mM *trans*-ferulate (F) or 10  
10 mM *trans*-ferulate plus 10 mM vanillate (FV). Cultures were previously grown in MM medium containing 10 mM vanillate.

Figure 3 indicates the changes in *trans*-ferulate and vanillate concentrations during growth of strain AN103 on MM medium containing  
15 10 mM *trans*-ferulate.

Figure 4 shows the production of vanillin (van) and vanillate (VA) by an extract of cells of strain AN103 (165  $\mu$ g protein) incubated with *trans*-ferulate, ATP, CoASH and  $Mg^{2+}$  ions, both in the absence of  $NAD^+$   
20 and in its presence (0.5mM). Cells were grown in the presence of 10 mM *trans*-ferulate, plus 10 mM vanillate.

Figure 5 demonstrates the formation of feruloyl SCoA, vanillin and acetyl SCoA from *trans*-ferulate supplied to a PD10-treated extract of  
25 *trans*-ferulate-grown cells of strain AN103 ( 7 $\mu$ g protein) in the presence of ATP, CoASH and  $Mg^{2+}$  ions.

Figure 6 demonstrates the production of vanillin, acetyl SCoA and feruloyl SCoA from HMPHP SCoA supplied to a PD10-treated cell-free extract (7 $\mu$ g protein) of *trans*-ferulate-grown cells of strain AN103.

- 5 Figure 7 shows the induction over time of *trans*-ferulate:CoASH ligase activity in response to 10 mM *trans*-ferulate (F), 10 mM vanillate (V) and 10 mM *trans*-ferulate plus 10 mM vanillate (FV) present in MM medium. The inocula were grown in MM medium plus 10 mM vanillate; growth conditions, enzyme extraction and assay were as described in Examples  
10 1 and 2.

Figure 8 shows SDS-PAGE of A), an extract of cells grown in MM medium with 10 mM *trans*-ferulate, electrophoresed at successive stages of purification of the HMPHP SCoA cleavage enzyme; successive stages  
15 are Crude Extract, Mono Q-purified, Mono-P-purified and Phenyl Superose-purified, and B), extracts of cells grown in MM medium with either 10mM vanillate or 10mM *trans*-ferulate and electrophoresed alongside Mono-P-purified cleavage enzyme; A) silver-stained; B) Coomassie-stained.

20

Figure 9 shows EcoRI/PstI digests of cosmid clones pFI793, pFI794, pFI795 and pFI796 separated on an agarose gel.

Figure 10 shows the sequence of the redundant primers designed from  
25 N-terminal amino residues of the 31-kDal protein (SEQ ID Nos. 5 and 6).

Figure 11 shows a Southern blot of EcoRI/PstI digests of various cosmid clones probed with the PCR product amplified using the N-terminal degenerate oligonucleotide primers as shown in Figure 10.

- 5 Figure 12 shows the nucleotide sequence of pFI989 (ie the 4370 bp EcoRI/PstI fragment from pFI794), together with the succeeding 882bp determined from a further subclone, pFI1056 and from pFI794 itself (SEQ ID No 7). The amino acid sequence of the 31 kD protein and that corresponding to the succeeding open reading frame encoding  
10 vanillin:NAD<sup>+</sup> oxidoreductase (vanillin dehydrogenase) (SEQ ID Nos. 2 and 4) are also shown.

Figure 13 shows the nucleotide sequence of pFI901 (ie the 1.8 kb EcoRI/PstI fragment from pFI793) (SEQ ID No 8).

15

Figure 14 shows the nucleotide sequence of pFI911 (ie the 850 bp EcoRI/PstI fragment from pFI793) (SEQ ID No 9).

- Figure 15 shows the nucleotide sequence of pFI912 (ie the 958 bp  
20 EcoRI/PstI fragment from pFI793) (SEQ ID No 10).

Figure 16 shows the nucleotide sequence of pFI913 (ie the 959 bp EcoRI/PstI fragment from pFI793) (SEQ ID No 11).

- 25 Figure 17 is a diagrammatic representation of the outward reading primers for pFI901 (P35 and P39), pFI911 (P32 and P36), pFI912 (P33 and P37) and pFI913 (P34 and P38).

Figure 18 is a diagrammatic representation showing the formation of the 1.5 kb PCR product, using primers P34 and P39, which spans the region in the cosmid between the inserts of pFI913 and pFI901.

- 5 Figure 19 shows the nucleotide sequence of the merged contigs pFI913/PCR product/pFI901 (4259 bp) (SEQ ID No 12).

**Example 1: Isolation and growth of *Pseudomonas fluorescens* biovar. V, strain AN103**

10

**Experimental**

*Growth media*

- 15 Organisms were grown on the following media:  
Minimal Medium (MM) contained, per l:  $\text{KH}_2\text{PO}_4$ , 5g;  $(\text{NH}_4)_2\text{SO}_4$ , 1g;  $\text{FeSO}_4$ , 0.5 mg;  $\text{CaCl}_2$ , 0.5 mg;  $\text{MnCl}_2 \cdot 5\text{H}_2\text{O}$ , 5 mg;  $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ , 1.1 mg;  $\text{MgSO}_4$ , 5 mg; EDTA, 50 mg;  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 28 mg;  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 1.6 mg;  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ , 1.6 mg. The pH was 7.0. Carbon  
20 sources were included as indicated.

- Tryptone- and yeast-based medium (LBMod) contained, per l : tryptone (Bacto; Difco, Detroit, USA), 10 g; yeast extract (Bacto), 5 g; NaCl, 10 g. The pH was adjusted to 7.5. LB Medium was identical with LB Mod,  
25 with the addition of glucose (1g/l).

Solid media were prepared with the addition of agar ( Difco), 15 g/l.

*Isolation of Pseudomonas fluorescens biovar. V, strain AN103*

The organism was isolated from surface soil, on the basis of ability to grow on *trans*-ferulate as sole carbon source. Initially, a 1g soil sample  
5 was added to 100ml sterile Minimal Medium (MM), containing *trans*-ferulic acid (10 mM). After 2 weeks at 25°C, with shaking at 200 rpm, a sample (100µl) was removed and added to 200ml of fresh medium containing 10mM *trans*-ferulic acid; this was repeated twice. Serial  
10 dilution onto solid medium (MM) containing 10mM *trans*-ferulate as sole carbon source enabled isolated colonies to be obtained which were replica-plated onto MM plates containing individual substrates as carbon sources. Several strains able to use *trans*-ferulate as sole carbon source were isolated - one (AN103), which was capable of growing also on vanillin, was selected for further work.

15

*Growth of strain AN103*

The organism was grown routinely at 25°C on MM, with shaking, using vanillic acid (10mM) or *trans*-ferulic acid (10mM) as sole carbon source;  
20 50ml of medium was used in a 250ml Erlenmeyer flask. Growth was monitored by measuring absorbance at 550 or 600nm.

For long-term storage, bacteria from logarithmic-phase cultures were centrifuged and then resuspended in Minimal Medium (MM) containing  
25 50% glycerol. They were then stored at -70°C. Cultures from these frozen stocks were reinitiated by transfer onto LB or LB-MOD solid medium, followed by inoculation into liquid medium containing 10mM *trans*-ferulic acid.



## Results

The organism was isolated from soil samples rich in decayed vegetation and was shown to be a strain of *Pseudomonas fluorescens* using standard  
5 identification techniques. As shown in Table I, the bacterium would grow not only on *trans*-ferulate as sole carbon source, but also on several closely-related compounds, including vanillate, protocatechuate and caffeate. Growth on vanillin was observed at low concentrations ( $< 1\text{mM}$ ) but was variable; higher concentrations were growth-inhibitory. If the  
10 organism was grown on vanillate, transfer to medium containing *trans*-ferulate as sole carbon source was followed by a lag in the growth curve; this was not observed if the transfer was to medium containing both vanillate and *trans*-ferulate (Fig 2). During a growth cycle on *trans*-ferulate, a transient increase in vanillate was observed at around the  
15 time when *trans*-ferulate disappearance was maximal (Fig 3), suggesting that vanillate was a catabolite of *trans*-ferulate. A small amount of protocatechuate was also observed when the culture medium was examined by TLC (not shown).

**Table I: Relative growth of *Ps. fluorescens* biovar. V, strain AN103 on a range of carbon substrates**

Substrates were provided in MM Medium at 10 mM concentration (vanillin, 1mM) and relative growth after 48h at 25°C was monitored by measuring absorbance at 600 nm.

Substrates	Relative Growth (%)
Ferulic acid	100
Caffeic acid	79
Sinapic acid	0
Cinnamic acid	0
Vanillin	< 100
Vanillic acid	140
Protocatechuic acid	77
Protocatechuic aldehyde	0
Glucose	221
Acetate	47
Methanol	0

**Example 2: *Trans*-ferulate metabolism in cell-free extracts and mechanism of cleavage**

**Experimental**

*Chemicals*

Chemicals and biochemicals were routinely obtained from Sigma Chemical Co. Ltd, Poole, Dorset, UK, Aldrich Chemical Co. Gillingham, Dorset,

UK or BDH-Merck, Poole, Dorset, UK. The synthesis of CoASH thioesters is described below.

*Preparation of 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionyl SCoA*  
5 *(HMPHP SCoA)*

This compound was prepared starting from a Reformatsky condensation of vanillin with ethyl bromoacetate (see R.L. Shriner, *The Reformatsky Reaction* in "*Organic Reactions*", R. Adams, W.E. Bachmann, L.F. Fieser, J.R. Johnson and H.R. Snyder, eds., vol. 1, pp 1-37, John Wiley, New York [1942]), followed by purification of the resulting ethyl 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionate (ethyl HMPHP) by HPLC, hydrolysis to the free acid, *N*-succinimidylation and, finally, exchange of the *N*-succinimidyl group with CoASH and isolation of the  
10 CoASH thioester by preparative TLC (see V. Semler, G. Schmidtberg and G.G. Gross, *Z. Naturforsch.* **42c**, 1070-1074 [1987]).  
15

Vanillin (3g) was mixed with 1.9 ml of ethylbromoacetate and 2g of dry Zn dust in 60 ml of dry 1,4-dioxane in a round-bottomed flask fitted with  
20 drying tubes and a reflux condenser. The reaction mixture was heated gently to boiling using a heating mantle and refluxed gently for *ca.* 1h. After being allowed to cool, the mixture was acidified with 60 ml of 10% H<sub>2</sub>SO<sub>4</sub> and extracted with 4 x 120 ml of diethyl ether. The combined ether phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and unreacted vanillin was  
25 removed by washing with 3 x 100 ml of sat. K<sub>2</sub>S<sub>2</sub>O<sub>5</sub>. The ether phase was then rotary evaporated under vacuum at *ca.* 30°C to remove the ether, leaving a liquid residue (*ca.* 10ml). This was then applied to a preparative C-18 reverse-phase HPLC column (Dynamax 60A, 8 $\mu$ m,

250mm x 41mm; Rainin, Woburn, MA, USA) and eluted at 12 ml min<sup>-1</sup> with a gradient of MeOH/H<sub>2</sub>O, containing 1mM trifluoroacetic acid. [Solvent A comprised 40% MeOH/1mM trifluoroacetic acid; solvent B comprised 100% MeOH/1mM trifluoroacetic acid; at time = 0 min, solvent was 20% B, rising linearly to 40% B at 28 min and 100% B at 35 min]. Fractions were monitored by absorbance at 280 nm and material eluting between 37 and 45 min was collected. The solvent was removed under vacuum at *ca.* 35°C and the remaining material brought to -20°C overnight. The precipitate which formed was then filtered off rapidly and freeze-dried to give 300mg of white substance. This was identified as 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxypropionic acid ethyl ester (ethyl HMPHP) by MS [M<sup>+</sup>]=240 and, on alkaline hydrolysis (1M KOH; 30 min), gave rise to the free acid.

To generate the *N*-succinimidyl ester, 30 mg of ethyl HMPHP was hydrolysed for 40 min at room temperature in 0.5 ml of 1M KOH. Oxalic acid (0.6 ml of 0.5 M) was then added to bring the pH to *ca.* 3-4. The solution was extracted successively with Et<sub>2</sub>O (5 x *ca.* 10ml); the organic phases were then pooled and evaporated to dryness. *N*-Hydroxysuccinimide (0.1 mmol; 11.5 mg) was then added in 1.2 ml of dry 1,4-dioxane. This was then followed, gradually, by 0.1 mmol (20.7 mg) of dicyclohexylcarbodiimide in 0.6 ml of dry 1,4-dioxane. The reaction mixture was allowed to stand at room temperature for *ca.* 4h and then filtered to remove precipitated DCU, a further 1.8 ml of dry dioxane being added to wash the filter.

The *N*-succinimidyl ester was not isolated from the reaction mixture but was converted *in situ* into the CoASH thioester. Lithium CoASH (40 mg;

*ca.* 0.05 mmol) was dissolved in 2.4 ml of 0.1M NaHCO<sub>3</sub> and the reaction mixture was added; the exchange reaction was performed under N<sub>2</sub>, with stirring, for *ca.* 2h at room temperature. The pH of the mixture was then adjusted to *ca.* 3-4 by the addition of 70  $\mu$ l of 2.8 M HCl and the mixture was stored at -70°C. The CoASH thioester of HMPHP was finally isolated by preparative TLC. Cellulose TLC plates (Avicel; 1000  $\mu$ m; Analtech, Newark, DE, USA), to each of which was applied 200  $\mu$ l of reaction mixture, were developed in *n*BuOH/ HOAc/ H<sub>2</sub>O (5/2/3, v/v/v). The CoASH thioester was localised at R<sub>F</sub> 0.4 - 0.5 using a short-wave u/v lamp and recovered from the plate by scraping and elution with 50% MeOH. Identification was confirmed by MS [*M*<sup>-</sup>=960] and by hydrolysis to the free acid (cf. ethyl HMPHP) which was measured by HPLC and used routinely as the basis for assay. The CoASH thioester showed an absorption maximum at 258 nm, and lacked the absorption maximum at 345nm characteristic of *trans*-feruloyl SCoA. This molecule - and the corresponding ethyl ester and free acid - carry an asymmetric centre at the  $\beta$ -carbon; however, no attempt was made here to resolve the optical isomers during or after synthesis.

#### 20 *Preparation of vanilloyl SCoA*

Vanilloyl SCoA was produced from vanillic acid via the *N*-succinimidyl ester, essentially according to the method described by V. Semler, G. Schmidtberg and G.G. Gross (*Z. Naturforsch.* **42c**, 1070-1074 [1987]) for the synthesis of piperoyl SCoA.

To a stirred solution of vanillic acid (5 mmol) and *N* - hydroxysuccinimide (5 mmol) in 30 ml of dry 1,4-dioxane was added, in

small portions, 7.5 mmol of solid dicyclohexylcarbodiimide. The solution was stirred overnight at room temperature, and precipitated DCU was removed by filtration. The filtrate was evaporated under reduced pressure at 40°C and the oily residue dissolved in boiling  $\text{CHCl}_3$ . The *N*-succinimidyl vanillate was crystallised from solution by the dropwise addition of petroleum ether (b.p.: 30°C - 40° C). Approx 750 mg was recovered.

To generate vanilloyl SCoA from *N* - succinimidyl vanillate, CoASH (sodium salt; 200 mg) was dissolved in 4 ml of 0.1 M  $\text{NaHCO}_3$ . *N* - Succinimidyl vanillate (120mg in 4 ml of dioxane) was then added gradually over a *ca.* 40 min period at room temperature, sparging with  $\text{N}_2$ . A further 4 ml of 0.1M  $\text{NaHCO}_3$  was then added, together with a further 8 ml of dioxane. Incubation under  $\text{N}_2$  at room temperature, with stirring, was continued for a further 1h. The pH was then adjusted to *ca.* 2.8 with 1M HCl and the solution was frozen and stored at -70°C. Isolation of vanilloyl SCoA was by preparative TLC, as described above with *n* BuOH/HOAc/ $\text{H}_2\text{O}$ (5/2/3, v/v/v) as solvent. Vanilloyl SCoA ( $R_F$ . 0.5-0.6) was identified using a short-wave u/v lamp and recovered by scraping, elution with 40% MeOH and freeze-drying. Identification was confirmed by MS ( $[M^-]=916$ ) and the thioester liberated vanillic acid on alkaline hydrolysis.

#### *Preparation of trans-feruloyl SCoA and other cinnamoyl SCoA thioesters*

25

*Trans*-feruloyl SCoA was prepared from *trans*-ferulic acid via the *N* - succinimidyl ester, as described above for vanilloyl SCoA. Final isolation was achieved similarly by preparative TLC and elution, identification

being confirmed by MS and by alkaline hydrolysis to free *trans*-ferulic acid. Caffeoyl and *p*-coumaroyl-S-CoA thioesters were prepared similarly.

#### *Preparation of cell-free extracts*

5 Cell-free extracts of logarithmic-phase cultures (6-10h after inoculation) were prepared by sonication. Cells from *ca.* 200ml of medium were pelleted by centrifugation, and resuspended in 5-10ml of Extraction Buffer (routinely 40mM KPi; pH 7.2, containing 10mM dithiothreitol). They  
10 were then sonicated (MSE Soniprep 150; Fisons Instruments, Crawley, Sussex, UK) at 4°C (5 x 20s; 22 Amplitude microns on full power), and centrifuged (20 000 x g; 20 min; 4°C). Extracts were routinely stored frozen at -70°C and in some instances buffer-changed using a PD10 column (Pharmacia) before use. The protein contents of extracts were  
15 variable - between 0.25 and 1.8 mg/ml.

#### *Incubation of cell-free extracts*

Cell-free extracts were routinely incubated at 30°C and pH 7.5 in a  
20 reaction mixture (1ml) containing 90mM Tris HCl buffer and 2.5mM MgCl<sub>2</sub>, together with (as appropriate) 0.5mM *trans*-ferulic acid, 0.2mM CoASH (Li salt) and 2.5 mM ATP. This complete reaction mixture constituted an assay for *trans*-ferulate: CoASH ligase, where the initial increase in absorbance at 345 nm was monitored against a blank reaction  
25 mixture from which CoASH was omitted. Incubations with HMPHP S-CoA (generally 0.4mM) were performed similarly, but with the omission of *trans*-ferulic acid, CoASH and ATP.

Vanillin: NAD<sup>+</sup> oxidoreductase was assayed at 30°C and pH 7.0 by monitoring the initial decrease in absorbance at 340 nm against a blank cuvette from which NAD<sup>+</sup> was omitted. Because of the similarity in extinction coefficient at 340nm for vanillin and for NADH, the sensitivity  
5 of the assay was increased by catalysing the regeneration of NADH to NAD<sup>+</sup> by providing lactate dehydrogenase and pyruvate. Reaction mixtures contained, in 1ml volume, 75 mM KPi buffer, pH 7.0, 0.125mM vanillin, 1.2 mM Na pyruvate, lactate dehydrogenase (rabbit muscle), 1.1 U and NAD<sup>+</sup>, 0.5 mM.

10

#### *HPLC analysis*

Metabolites of *trans*-ferulic acid, including the CoASH thioesters, were analysed and quantitated by HPLC using a Lichrosorb RP-18 column (20  
15 cm x 4.6 mm; Capital HPLC, Broxburn, West Lothian, UK) with a multiphasic gradient; solvent "A" was 20mM NaOAc, adjusted to pH 6.0 and solvent "B" was MeOH; the flow rate was 1.2 ml/min; the proportion of solvent "B" rose linearly from 0% at 0 min to 10% at 15 min and thence to 50% at 40 min and 70% at 45 min, finally decreasing to 0% at  
20 50 min. Detection was with a Spectra Focus detector (Thermo Separation Products, Stone, Staffs. UK), which permitted u/v spectral analysis of each eluting component.

Typical approximate retention times were: CoASH, 3 min; vanillic acid, 7 min; *trans*-ferulic acid, 19 min; acetyl SCoA, 22 min; HMPHP SCoA,  
25 29 min; vanilloyl SCoA, 31 min; vanillin, 31.5 min; *trans*-feruloyl SCoA, 34 min.



### Mass spectrometry

Mass spectra (+-ve and --ve ion) were recorded on a MS 9/50 mass spectrometer (Kratos Instruments, Manchester UK), using xenon fast atom bombardment (FAB) at a potential of 5-7 kV using glycerol as matrix (see 5 G.R. Fenwick, J. Eagles and R. Self, *Biomedical Mass Spectrometry* 10, 382-386 (1983)).

### Protein assay

10

Protein was assayed by the method of M.M. Bradford (*Anal. Biochem.* 72, 248-254 (1976)), using Bio-Rad dye reagent (Bio-Rad Laboratories, Richmond, CA, USA) and bovine serum albumin as standard.

## 15 Results

Crude extracts of *Ps. fluorescens* biovar. V, strain AN103, from cells grown on vanillate together with *trans*-ferulate, were able to produce vanillate when supplied with *trans*-ferulate, CoASH, ATP,  $Mg^{2+}$  ions and 20  $NAD^{+}$ . In the absence of  $NAD^{+}$ , vanillate was not formed and vanillin accumulated in its place (Fig 4). The quantity of vanillin formed in the absence of  $NAD^{+}$  was smaller than the amount of vanillate formed in its presence. Essentially no vanillin accumulated in the presence of  $NAD^{+}$ .

25 This utilisation of *trans*-ferulate by crude extracts was dependent upon CoASH and ATP and partially upon  $Mg^{2+}$  ions (Table II). These properties indicate an initial activation of *trans*-ferulate to *trans*-feruloyl SCoA by *trans*-ferulate: CoASH ligase. This was further shown by the

rapid development of a CoASH-dependent absorbance maximum at 345 nm and particularly by a transient bathochromic shift, causing the appearance of a yellow colour, if the reaction mixture was made alkaline with NaOH (data not shown). In the initial stages of the overall reaction, the linear increase in absorbance at 345 nm enabled the activity of *trans*-ferulate: CoASH ligase to be assayed directly. During the later stages, however, absorbance at 345 nm would be contributed by both *trans*-feruloyl SCoA and vanillin or, in the presence of NAD<sup>+</sup>, NADH, each of which has substantial absorbance at this wavelength.

**Table II: Cofactor requirements for *trans*-ferulate utilisation by *P. fluorescens* biovar. V, strain AN103 cell-free extracts**

Reaction mixtures (165 µg protein) were incubated for 4h at 30°C as described in Experimental, with omissions from the complete reaction mixture as indicated.

Reaction Mixture	Reaction products (nmol)		
	<i>Trans</i> -ferulate (remaining)	Vanillin	Vanillate
Complete	267	n.d.	311
-CoASH	550	n.d.	40
-NAD <sup>+</sup>	258	228	23
-ATP	513	n.d.	33
-Mg <sup>2+</sup>	425	n.d.	153

n.d. = not detectable

An overall non-oxidative cleavage of *trans*-feruloyl SCoA is implied in Fig 5 which shows, in the absence of NAD<sup>+</sup>, an equivalence between the

formation of vanillin and that of acetyl SCoA. (The formation of [2-<sup>13</sup>C] acetyl SCoA from *trans*-ferulate <sup>13</sup>C-labelled in the  $\alpha$ -carbon atom was also confirmed by NMR spectroscopy (not shown).) The cleavage mechanism was investigated further by synthesising chemically the hydrated derivative of *trans*-feruloyl SCoA, 4-hydroxy-3-methoxy-phenyl- $\beta$ -hydroxypropionyl SCoA (HMPHP SCoA). This was incubated with cell-free extract and shown to be converted rapidly to acetyl SCoA and vanillin, in equimolar proportions (Fig 6). A smell of vanillin was obtained when HMPHP SCoA was used as a substrate. This hydrated intermediate was not only metabolised in the forward direction, however, since an almost equivalent back reaction to feruloyl SCoA (putatively *trans*) was also observed. The rapidity of utilisation of HMPHP SCoA was consistent with the failure to observe its accumulation, using HPLC, during cell-free incubations with *trans*-ferulate, CoASH, ATP and Mg<sup>2+</sup> ions. This cleavage of HMPHP SCoA in the absence of NAD<sup>+</sup> indicated no intervening  $\beta$ -oxidation to the  $\beta$ -keto thioester (4-hydroxy-3-methoxybenzoyl) acetyl SCoA (*cf.* M.H. Zenk, *Anal. Z Pflanzenphysiol* **53**, 404-414 (1965)). Attempts to prepare this compound for cell-free studies were unsuccessful, but its expected cleavage product, vanilloyl SCoA, was prepared and shown not to be metabolised to vanillin by cell-free extracts in the presence of NADH, even when simultaneous incubations with *trans*-ferulate in the absence of NAD<sup>+</sup> actively produced vanillin.

Besides *trans*-ferulic acid, caffeic acid and *p*-coumaric acids were converted to thioesters of CoASH by crude extracts of *Ps. fluorescens* biovar. V, strain AN103 (Table III).

**Table III.** Formation of CoASH thioesters of *trans-p*-hydroxycinnamic acids by crude extracts of *Ps. fluorescens* AN103. The activity was assayed spectrophotometrically as described for *trans*-ferulate: CoASH ligase, measuring the initial rate of increase in absorbance at 345 nm in the case of *trans*-feruloyl SCoA formation, and at the corresponding absorbance maxima for the other SCoA thioesters.

Substrate	Activity (nkat/mg protein)
Ferulate	0.50
Caffeate	0.39
<i>p</i> -Coumarate	0.37

**Example 3: Mutants in *trans*-ferulate metabolism**

**Experimental**

*Mutagenesis of Pseudomonas fluorescens biovar. V, strain AN103*

Ethyl methanesulphonate (EMS) was used for mutagenesis. Bacteria were grown for 2 d at 25°C in minimal medium (MM) with vanillic acid as carbon source; 1 ml of culture was then inoculated into 50 ml of LB-MOD and grown for 16 h at 25°C. The cells were centrifuged and resuspended in 0.1M KH<sub>2</sub>PO<sub>4</sub> (1.25 ml) to give a cell density of 4 x 10<sup>9</sup> cells/ml (OD<sub>580</sub> of 1.0 = 6 x 10<sup>7</sup> cells/ml). An aliquot of this cell suspension was serially diluted (10<sup>-2</sup> -10<sup>-8</sup>) and plated onto LB-MOD plates (0.1 ml per plate) to provide control cell counts for assessment of the efficiency of mutagenesis.

A cell suspension (1 ml) was incubated with 0.08 ml of EMS in a total of 3 ml of 0.1M  $\text{KH}_2\text{PO}_4$  at 37°C for 45 min. The cells were then precipitated by centrifugation at 4°C and the cell pellet was washed twice with 10 ml of LB-MOD medium, prior to resuspension in 1 ml of this medium. An aliquot was serially diluted ( $10^{-2}$ - $10^{-8}$ ) and plated onto LB-MOD plates; these were incubated at 25°C overnight, together with the plates of the unmutagenised cells, to obtain an estimate of kill (70% kill indicates efficient mutagenesis). The remaining mutagenised cells (0.9 ml) were inoculated into LB-MOD medium (50 ml) and incubated overnight at 25°C. The mutagenised cells were then enriched for mutants in *trans*-ferulate utilisation by treatment with carbenicillin in minimal medium (MM) in the presence of *trans*-ferulic acid. The cells were harvested by centrifugation at 4°C, washed twice with MM (10 ml) and resuspended in 20 ml of MM. A sample (1 ml) was inoculated into MM (15 ml) and incubated at 25°C for 1 h; then *trans*-ferulic acid (10mM final concentration) and carbenicillin (2 mg/ml final concentration) were added. A control flask was prepared containing *trans*-ferulic acid, but not carbenicillin. Both flasks were incubated overnight at 25°C for 16 h, monitoring  $\text{OD}_{580}$  to estimate growth and confirm the effectiveness of the antibiotic. Penicillinase (10 units) was then added to destroy the carbenicillin, incubating overnight at 25°C. The cells were harvested by centrifugation at 4°C, washed twice in MM (10 ml) and resuspended in 5 ml of MM; 1 ml of these resuspended cells were then inoculated into 50 ml of MM containing 10mM vanillic acid and incubated at 25°C for *ca.* 24 h.

These enriched cells were screened by replica-plating for mutants unable to use *trans*-ferulic acid. The enriched stock was diluted to  $10^{-6}$ , plated

onto LB-MOD (0.1 ml per plate), incubated at 25°C for 2 d and then replica-plated onto MM containing 10mM vanillic acid or 10mM *trans*-ferulic acid. The plates were incubated at 25°C for 2-3 d and screened for colonies able to grow on vanillate but unable to grow on *trans*-ferulate.

5

## Results

By mutagenesis of strain AN103 with ethyl methane sulphonate, two classes of mutants unable to utilise *trans*-ferulate as sole carbon source were isolated; these were van 1, van 2 and van 3 and, secondly, van 10 and van 11. Following growth on vanillate plus *trans*-ferulate, a representative of the first of these, van 1, showed no activity in cell-free incubations with either *trans*-ferulate or vanillin and lacked both *trans*-ferulate: CoASH ligase and the enzyme that converts vanillin to vanillate, vanillin: NAD<sup>+</sup> oxidoreductase. In contrast, the type representative of the second class, designated van 10, possessed levels of activity of both *trans*-ferulate: CoASH ligase and vanillin: NAD<sup>+</sup> oxidoreductase similar to those found in strain AN103, but in the presence of NAD<sup>+</sup> generated very little vanillate (Table IV). Cell-free extracts of van 10 were examined further for their ability to metabolise HMPHP SCoA. They metabolised this thioester actively, but appeared predominantly to dehydrate it to feruloyl SCoA; vanillin formation was substantially inhibited in comparison to the AN103 extract (Table V). These observations suggested that van 1 was a regulatory mutant, defective in its induction by *trans*-ferulate, whilst van 10 appeared to be defective in the HMPHP SCoA cleavage activity.

25

**Table IV: *Trans*-ferulate metabolism in cell-free extracts of *P. fluorescens* biovar. V, strain AN103 and of mutant strains *van* 1 and *van* 10.**

- 5 Cells were grown for 6h in MM medium containing 10 mM vanillate together with 10 mM *trans*-ferulate. Extracts were then prepared as in Example 2 and assayed for *trans*-ferulate:CoASH ligase and vanillin:NAD<sup>+</sup> oxidoreductase. Extracts (*ca.* 0.3 mg of protein) were also incubated for 4h in the presence of NAD<sup>+</sup> to determine relative amounts  
10 of vanillate formed.

Strain	Enzyme activity (nkat mg <sup>-1</sup> protein)		Vanillate formed (nmol mg <sup>-1</sup> protein)
	Ferulate: CoASH ligase	Vanillin: NAD oxidoreductase	
AN103	1.7	1.2	807
<i>van</i> 1	0	~0.05	0
15 <i>van</i> 10	2.0	1.4	59

**Table V: Utilisation of HMPHP SCoA by extracts of *Ps. fluorescens* biovar. V, strains AN103 and *van* 10**

- 20 Extracts (AN103, 14 µg protein; *van* 10, 68 µg protein) were incubated at 30°C for 7 min in 1 ml vol containing 0.3 mM HMPHP SCoA. The increase in absorbance at 345 nm was measured against a blank reaction mixture containing no extract. Vanillin formation was measured by HPLC; the production of feruloyl SCoA was in this instance calculated  
25 from the increase in absorbance at 345 nm, after subtraction of the contribution from vanillin.

Strain	$\Delta A_{345}$	Feruloyl SCoA (nmol)	Vanillin (nmol)
AN103	0.75	18.4	23.8
van 10	0.63	29.2	4.5

5 **Example 4: Induction of *trans*-ferulate metabolism in strain AN103 and purification of HMPHP SCoA cleavage enzyme**

**Experimental**

10 *Purification of trans-feruloyl SCoA hydratase/aldol cleavage enzyme*

Cells (from 2 l of culture grown for 72 h on MM with 10mM *trans*-ferulic acid as substrate; OD<sub>565</sub> ca.=0.5) were extracted essentially as described in Example 2 to give 50 ml of crude extract, containing 1.28 mg of  
15 protein/ml.

Extract (16 ml, diluted to 40 ml), was applied at room temperature and 2 ml/min to a Mono Q HR10/10 anion-exchange column (Pharmacia, Piscataway, NJ, USA), preequilibrated with 20 mM Tris buffer (pH 7.5)  
20 containing 10 mM dithiothreitol. After elution of unadsorbed protein, protein bound to the column was eluted with a linear gradient of increasing NaCl concentration: from 0 to 0.5M NaCl in 100 ml of buffer.

Fractions eluting between 0.18 and 0.3 M NaCl and containing activity  
25 with HMPHP SCoA, as determined using the microtitre plate assay (see below), were pooled and buffer-changed by dialysis into 25 mM bis-Tris buffer, containing 10 mM dithiothreitol and adjusted to pH 7.1 with



iminodiacetic acid. They were then applied at 0.75 ml/min to a Mono P HR 5/20 chromatofocusing column (Pharmacia), preequilibrated with the same buffer. After eluting unadsorbed protein from the column, adsorbed protein was eluted with a gradient of decreasing pH, generated by  
5 applying 46 ml of 10% (v/v) Polybuffer 74 (Pharmacia), containing 10 mM dithiothreitol and adjusted to pH 4.0 with iminodiacetic acid. Activity with HMPHP SCoA was eluted between pH 5.5 and 5.1.

The active fractions were again pooled together, and buffer-changed into  
10 20 mM Tris buffer (pH 7.5), containing 1.7 M  $(\text{NH}_4)_2\text{SO}_4$  and 10 mM dithiothreitol, using PD10 columns (Pharmacia), before application at 0.5 ml/min to a PhenylSuperose HR 5/5 hydrophobic interaction chromatography column (Pharmacia) preequilibrated with this buffer. Elution of bound protein was achieved with a decreasing gradient of  
15  $(\text{NH}_4)_2\text{SO}_4$  in buffer, from 1.7 M to zero over 30 ml and then continuing with buffer alone for a further 5 ml. Activity with HMPHP SCoA was eluted in this final 5 ml of buffer.

At each stage of purification, active fractions were detected by a micro-  
20 adaptation of the assay with HMPHP SCoA described above (Example 2); reactions were performed in 100  $\mu\text{l}$  of reaction mixture for *ca.* 4 min at room temperature in microtitre wells and absorbance was then measured in an MR 5000 microtitre plate reader (Dynatech, Guernsey, Channel Islands), equipped with a 340 nm filter. The activity of the pooled  
25 fractions was measured using HPLC to determine the reaction products of both HMPHP SCoA, (0.4mM) and *trans*-feruloyl SCoA (0.28mM) as substrates. Reaction mixtures containing 10  $\mu\text{l}$  of enzyme were incubated in 100  $\mu\text{l}$  volume as described above; the reaction was terminated with

100  $\mu$ l of acidified MeOH (pH 3) after 2 min (HMPHP SCoA) or 5 min (*trans*-feruloyl SCoA) of incubation at 24°C. The proportionality of the reactions with time and with quantity of enzyme was established in preliminary determinations.

5

Samples (10 $\mu$ l) of enzyme at each stage of purification were analysed by SDS-PAGE, with Coomassie or silver staining, essentially as described by H. Schagger and G. von Jagow, *Anal. Biochem.* **166**, 368-379 (1987). An Atto AE6450 gel apparatus was used (supplied by Genetic Research  
10 Instrumentation, Dunmow, Essex, UK).

Electroelution of protein bands from fixed, stained gels was performed using a Bio-Rad Model 422 electroeluter according to the manufacturer's directions. Eluted protein was then deposited by centrifugation onto a  
15 Pro-Spin membrane (Applied Biosystems, Foster City, CA, USA) used in accordance with the manufacturer's recommendations). N-Terminal sequencing was performed by Alta Bioscience, University of Birmingham, Birmingham, UK.

## 20 Results

The time-course of induction of *trans*-ferulate:CoASH ligase in strain AN103 is shown in Fig 7. Following transfer of vanillate-grown cells to medium containing *trans*-ferulate, the specific activity of the ligase in  
25 extracts increased approximately linearly over an 8-hour period. An essentially identical time-course was obtained if the cells were transferred instead to medium containing both *trans*-ferulate and vanillate. Vanillate,

a catabolite of *trans*-ferulate, therefore did not inhibit the induction process.

Induction of the capacity to grow on a different substrate represents a significant shift in primary metabolism, which in principle might be detectable by electrophoresis of a crude protein extract. Cell-free extracts analysed by SDS-PAGE, with Coomassie staining (see Experimental), did indeed show a distinct difference in protein banding between *trans*-ferulate-grown cells and vanillate-grown cells (Fig 8). Extracts from *trans*-ferulate-grown cells exhibited a new, or very strongly enhanced, band corresponding to a polypeptide of molecular weight *ca.* 31 kD.

N-Terminal amino acid sequencing of this polypeptide, following its removal from the gel by electroblotting, gave the following sequence: Ser-Thr-Tyr-Glu-Gly-Arg-Trp-Lys-Thr-Val-Lys-Val-Glu-Ile-Gln-Asp-Gly-Ile-Ala-Phe (SEQ ID No 13).

Purification of HMPHP SCoA-utilising activity was achieved by Fast Protein Liquid Chromatography (FPLC - Pharmacia). As described above, fractions were screened for activity with HMPHP SCoA using a microtitre plate scanner; active fractions were then pooled together and activity was then measured both with HMPHP SCoA and with *trans*-feruloyl SCoA, determining the reaction products by HPLC.

The results of the purification are given in Tables VI and VII. Vanillin and acetyl SCoA were produced in approximately equimolar amounts, throughout the purification, with either HMPHP SCoA or *trans*-feruloyl SCoA as substrate. There was an approximate copurification of the

activities with *trans* - feruloyl SCoA and HMPHP SCoA as substrate, including the formation of feruloyl SCoA from HMPHP SCoA (dehydratase reaction; reverse of reaction II): vanillin-forming activity from *trans*-feruloyl SCoA (reactions II+III) was purified 11.5-fold, 5 vanillin-forming activity from HMPHP SCoA (reaction III) was purified 11.7-fold and the dehydratase reaction (reverse of reaction II) was purified 9.1-fold. Approximately 20-25% of each of these activities was finally recovered.

10 **Table VI: Purification of *trans*-feruloyl SCoA hydratase/aldol cleavage enzyme.**

Purification from cells of *Ps. fluorescens* biovar V, strain AN103, was undertaken as described in Experimental, measuring activity - vanillin as 15 product - with both *trans*-feruloyl SCoA and HMPHP SCoA as substrates. Values in parentheses show activity measuring acetyl SCoA as product.

Part 1

Purification stage	Total activity (nkat)		Total protein (mg)	Specific activity (nkat/mg)	
	<i>trans</i> -feruloyl SCoA	HMPHP SCoA		<i>trans</i> -feruloyl SCoA	HMPHP SCoA
Crude Extract	85.2 (68.2)	59.2 (54.9)	20.5	4.16	2.89
Mono Q Fractions	80.6 (66.2)	45.1 (42.9)	4.37	18.4	10.3
25 Mono P Fractions	56.9 (51.9)	35.4 (33.4)	1.61	34.1	21.2
30 Phenyl Superose Fractions	22.1 (19.8)	15.5 (15.1)	0.46	48.0	33.7

## Part 2

Purification stage	Ratio of activities	Purification (fold)		Recovery (%)	
		<i>trans</i> -feruloyl SCoA	HMPHP SCoA	<i>trans</i> -feruloyl SCoA	HMPHP SCoA
Crude Extract	1.44	1.00	1.00	100	100
Mono Q Fractions	1.79	4.42	3.56	94.6	76.2
Mono P Fractions	1.61	8.20	7.34	66.8	59.8
Phenyl Superose Fractions	1.42	11.5	11.7	25.9	26.2

**Table VII: HMPHP SCoA dehydratase activity during purification of *trans*-feruloyl SCoA hydratase/aldol cleavage enzyme**

Conditions and other data as Table VI. Dehydratase reaction measured as feruloyl SCoA production.

Purification stage	Total activity (nkat)	Specific activity (nkat/mg)	Purification (fold)	Ratio to HMPHP SCoA Cleavage Activity*
Crude Extract	171	8.34	1.00	2.89
Mono Q Fractions	121	27.7	3.32	2.69
Mono P Fractions	101	60.5	7.25	2.85
Phenyl Superose Fractions	34.9	75.9	9.10	2.25

\* see Table VI.

SDS-PAGE of the combined active fractions at each stage revealed the enhancement of a 31 kD protein band (Fig. 8), indicating purification to apparent homogeneity after chromatography on PhenylSuperose (Pharmacia). This band co-migrated with the band associated with growth of strain AN103 on *trans*-ferulate and gave the same N-terminal amino-acid sequence: Ser-Thr-Tyr-Glu-Gly-Arg-Trp (SEQ ID No 14).

Definitive proof of the catalysis of both reactions II and III by this protein was achieved as a result of expression of the gene in *Escherichia coli*. (see Example 5).

The Mono-P-purified enzyme was able to accept, as alternative substrates to *trans*-feruloyl SCoA, *trans*-caffeoyl SCoA and *trans*-4-coumaroyl SCoA (Table VIII).

15

**Table VIII.** Utilisation of *trans*-*p*-hydroxycinnamoyl SCoA thioesters by *trans*-feruloyl SCoA hydratase/aldol cleavage enzyme. Activity was determined at 30°C and with 0.4 mM substrate using enzyme from *Ps. fluorescens* AN103 (2.8 µg of enzyme protein, partially purified by Mono-Q and Mono-P chromatography) as described in Experimental.

20

Substrate	Activity (nkat/mg of protein)
Feruloyl SCoA	0.60
Caffeoyl SCoA	0.36
<i>p</i> -Coumaroyl SCoA	0.72

25

**Example 5: Isolation of the genes required for the conversion of *trans*-feruloyl SCoA to vanillic acid (vanillate) in *Pseudomonas fluorescens* strain AN103**

- 5 A strain of *Pseudomonas fluorescens* (biovar. V, AN103) was isolated from soil at the Institute of Food Research, Norwich Laboratory, which was able to grow on *trans*-ferulic acid converting it to vanillic acid via vanillin. The proposed biochemical pathway for the conversion of *trans*-ferulic acid to vanillic acid shown in Fig 1 was substantiated in the  
10 experiments described above in Experiments 2 - 4.

In order to clone the genes required for the conversion of *trans*-feruloyl SCoA to vanillic acid the strategy of complementing mutant derivatives of *Ps. fluorescens* AN103 that were unable to grow on *trans*-ferulate as sole  
15 carbon source was used. The isolation and characterization of mutants is described above in Example 3 and mutants van10 and van11 were used for clone isolation. As described in Example 3, these mutants appeared to be defective in a gene involved in the conversion of *trans*-feruloyl SCoA to vanillin.

20

A genomic library of *Ps. fluorescens* AN103 DNA was prepared in the mobilisable cosmid cloning vector pLAFR3 (B. Staskawicz, D. Dahlbeck, N. Keen, and C. Napoli, *J. Bact.* **169**, 5789-5794 (1987)). Genomic DNA was isolated from *Ps. fluorescens* AN103 and partially digested  
25 with *Sau* 3A1 at 37°C for 7-10 min. The DNA was then size-fractionated on a NaCl gradient (1.25-5M). The fraction containing DNA of 20-40 kb was selected and 0.5 µg ligated into the dephosphorylated *Bam* H1 site of the broad- host-range cosmid cloning vector, pLAFR3. One half of the

ligation mix was packaged into bacteriophage lambda particles using a Gigapack II XL kit (Stratagene, La Jolla, CA, USA). The packaged cosmids were transfected into *Escherichia coli* strain 803 (W.B. Wood, *J. Mol. Biol.* **16**, 118-133 (1966)). Approximately 10,000 primary  
5 transfectants were obtained. The lawn of cells obtained was washed from the selection plates and glycerol-containing stocks prepared for storage at -70°C.

The genomic library of *Ps. fluorescens* AN103 DNA in cosmid pLAFR3  
10 was introduced into the two mutant *Ps. fluorescens* derivative strains van10 and van11 using the helper plasmid, pRK2013 (D. Figurski and D.R. Helinski, *Proc Natl. Acad. Sci. USA* **76**, 1648-1652 (1979)). The mutant strains were inoculated into minimal medium MM containing 10mM vanillic acid and incubated at 25°C for 2 days. The *Escherichia*  
15 *coli* strain carrying the helper plasmid (*E.coli* 803pRK2013) was inoculated into LB-Mod medium (10 ml) and incubated at 37°C for 6 h. At the same time, 0.1 ml of the glycerol-containing stock of the AN103 genomic library was similarly inoculated and incubated. The growth of all three cultures was monitored by measuring OD<sub>600</sub> and appropriate volumes  
20 combined in a centrifuge tube to give equal populations of the three organisms. The mixture of cells was centrifuged, resuspended in a minimal volume of the supernatant solution and spread over a sterile gridded cellulose nitrate membrane filter (47 mm diam., Whatman, Maidstone, Kent, UK) on a moist LB-Mod agar plate. The suspension  
25 was allowed to air-dry onto the filter for a few minutes and then incubated overnight at 25°C. The bacteria were then washed from the filter using 2 ml of H<sub>2</sub>O and aliquots (0.1 ml) were applied to selection plates consisting of MM agar with 10 mM vanillic acid and 5 µg/ml tetracycline. These



were incubated at 25°C for 2 days and the colonies obtained (> 1000 per plate) were replica-plated to similar plates containing *trans*-ferulic acid in place of vanillic acid; these were incubated similarly. Colonies (2-3 per plate) able to grow on the plates containing *trans*-ferulic acid were selected and inoculated into fresh MM medium containing 10 mM *trans*-ferulic acid and 5 µg/ml tetracycline. Four such isolates in which the mutation in the *Ps. fluorescens* strains van10 and van11 was complemented by the introduced cosmid were selected for further analysis. These strains were purified and the cosmid DNA was extracted by the mini-preparation method of F.G. Grosveld, H.H.M. Dahl, E. Deboer and R. A. Flavell (*Gene* 13, 227-231 (1981)). The cosmid DNA was transformed into *E. coli* strain 803 and was again isolated as described by D.S. Holmes and M. Quigley (*Anal. Biochem.* 114, 193-197 (1981)). Two of the cosmid clones, pFI 793 and pFI 794, were isolated as complementing *Ps. fluorescens* mutant strain van 10, whereas cosmid clones pFI 795 and pFI 796 complemented *Ps. fluorescens* mutant strain van 11.

To test whether the plasmid clones pFI 793, pFI 794, pFI 795 and pFI 796 would complement any of the other *Ps. fluorescens* mutants, each plasmid was introduced into *Ps. fluorescens* mutant strains van1, van2, van3, van10 and van11. As described above in Example 3 the mutant strains van1, van2 and van3 appear to be defective in a regulatory function that eliminates at least two different enzyme activities. The *Ps. fluorescens* van mutants were grown on MMO+10 mM vanillic acid agar medium for two days at 25°C. The strain carrying the helper plasmid (803pRK2013) was grown on LB-Mod agar + kanamycin (25 µg/ml) at 37°C overnight. The *E. coli* 803 cosmid clones carrying pFI 793, pFI 794, pFI 795 and pFI 796 were grown on LB-Mod agar medium +

tetracycline (5  $\mu$ g/ml) at 37°C overnight. The bacteria were patch mated (ie a loopful of donor, recipient and helper strain were mixed together on LB-Mod agar and incubated overnight at 25°C). The bacteria were replica plated onto selection medium (MMO + 10 mM *trans*-ferulic acid + tetracycline and MMO + 10 mM vanillic acid + tetracycline) and incubated at 25°C for two days. All four cosmid clones pFI 793, pFI 794, pFI 795 and pFI 796 complemented all of the van mutants (*van1*, *van2*, *van3*, *van10* and *van11*) enabling them to grow on *trans*-ferulate as sole carbon source.

The cosmid clone DNAs were analyzed by digestion with restriction endonucleases Hind III and *Eco* RI to reveal insert DNA. Each of the four clones pFI 793, pFI 794, pFI 795 and pFI 796 carried inserts of between 20 and 30 kb. The four cosmid clones gave distinct restriction patterns, but appeared to share some restriction fragments of the same size. To identify restriction fragments that were common to the cosmid clones cosmid pFI 793 was used as a probe against DNA of all four cosmid DNA preparations that had been double-digested with restriction endonucleases *Eco* RI and *Pst* I. Cosmid DNA was isolated using Qiagen midi columns according to the manufacturers instructions and was digested with restriction endonucleases *Eco*RI and *Pst*I. The resulting fragments were separated by agarose gel electrophoresis and Southern blotted to a Hybond-N filter as described by Sambrook *et al* (Sambrook, J., Fitch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor, NY, 1989). Cosmid pFI 793 DNA was linearised, denatured and labelled with digoxigenin prior to probing the Southern blotted DNA according to the instructions supplied by Boehringer (Lewes, Sussex, UK). The pFI 793 probe hybridised to all of

the EcoRI/PstI restriction fragments of pFI 795 indicating that these two clones are identical. Excluding the vector band at least six EcoRI/PstI fragments appeared to be common to pFI 793, pFI 794, pFI 795 and pFI 796. These were fragments of 6.6kb, 2.9kb, 1.8kb, 1.4kb, 1.25kb and 1.1 kb. The 1.25kb fragment appeared to be a doublet or triplet. The DNA fragment patterns of the four cosmid clones after restriction digestion with EcoRI/PstI are shown in Figure 9. For clarity the ethidium bromide stained DNA bands have been diagrammatically superimposed on the original agarose gel.

10

As described above in Example 4 protein analysis of *Ps. fluorescens* biovar. V, strain AN103 showed that cells grown on *trans*-ferulate contained much larger amounts of a protein of about 31 kD compared with cells grown on vanillic acid. The twenty N-terminal amino acids of this protein were sequenced. This amino acid sequence was then used to design degenerate oligonucleotide primers that enabled the 60 bp sequence of DNA coding for this N-terminus to be amplified from pFI 793 by PCR (Figure 10). This sequence was used to probe EcoRI/PstI digests of the cosmid clones. By this technique the fragment containing the region of DNA encoding the 31 kD protein in each of the cosmid clones could be identified (Figure 11). This proved to be a fragment of 6kb in cosmids pFI 793 and pFI 795, a fragment of 4.3kb in cosmid pFI 794 and a fragment of 5.5kb in cosmid pFI 796.

20

The 4.3 Kb EcoRI/PstI fragment of pFI 794 was sub-cloned into the *E. coli* vector pUC19 using strain XLI(Blue) and its nucleotide sequence was determined using an Applied Biosystems DNA Sequencer (Model 373; Perkin Elmer, Warrington, UK); together with the manufacturer's Taq

25

DyeDeoxy Terminator Cycle sequencing kit. A primer walking strategy was used with oligonucleotide primers being synthesized on an ABI 392 Synthesizer (Perkin Elmer, Warrington, UK). The DNA sequence of the 4.3kb fragment is presented in Figure 12. The open reading frame  
5 encoding the same amino-terminus as determined previously starts at position 2872 and is terminated by a stop codon at position 3700. This ORF of 828 bp encodes a protein 276 amino acids long with a molecular size of 31.010 kD in good agreement with the protein gel analysis. The translated amino-acid sequence of this gene is also presented in Figure 12.  
10 In order to confirm the function of this gene it was sub-cloned and expressed in *E. coli*. From the DNA sequence PCR primers were designed to amplify the gene such that it was flanked by restriction endonuclease sites *EcoRI* and *BamHI*. The amplified gene retained its native ribosome binding site being initiated at base -29 and ending 6bp  
15 downstream of the stop codon. The amplified fragment was cloned into the equivalent sites of the *E. coli* expression vector pSP72 (Promega, Southampton, UK) and transformed into *E. coli* JM109(DE3).

The *E. coli* 803 clones carrying the hydratase/cleavage enzyme gene, plus  
20 a putative promoter, as a PCR product in the vector pRK415 were used in a triparental patch mating experiment essentially as described earlier in relation to complementation by the cosmid clones pFI 793-6. The complemented van 10 strain was demonstrated to have recovered the ability to grow on *trans*-ferulic acid, confirming directly that the mutation  
25 in van 10 resided in the gene encoding the *trans*-feruloyl SCoA hydratase/cleavage enzyme.

The presence of a novel enzyme activity (*cf.* Example 4) in the *E. coli* clone was demonstrated. *E. coli* cells were grown at 37°C for 3 h in 50ml of L medium, containing ampicillin (50 µg/ml) with and without induction by IPTG. Extracts were prepared as described above in

5 Example 2 for *Ps. fluorescens* AN103, but without centrifugation. The crude extract was used for assay. Enzyme activity with both HMPHP SCoA and *trans*-feruloyl SCoA was determined as described above in Example 4 using HPLC to determine the reaction products. The results presented in Table IX clearly demonstrate that vanillin and acetyl SCoA

10 were produced in equimolar proportions both with *trans*-feruloyl SCoA and with HMPHP SCoA as substrates. In addition, HMPHP SCoA was also dehydrated to feruloyl SCoA, putatively *trans*-feruloyl SCoA, demonstrating the reverse of activity II. These results are closely similar to those obtained with the vanillin-forming cleavage enzyme purified from

15 *Pseudomonas fluorescens* AN103, although the ratio of activities with *trans* - feruloyl SCoA and HMPHP SCoA differs slightly between the two preparations. There was no activity with either *trans*-feruloyl SCoA or HMPHP SCoA in extracts of an unmanipulated *E. coli* strain, whether induced or not. In the manipulated strain *E. coli* 1039 that expresses the

20 *Pseudomonas* gene the specific activity was slightly lower in the extract made following induction than in that made from uninduced bacteria. Since the assay measures only active enzyme it is conceivable that increased protein expression occurs upon induction but this may result in incorrectly folded and therefore inactive enzyme. It was not possible to

25 detect expression of the 31kD protein visually on Coomassie-stained, one-dimensional SDS gels because of its co-migration with the strongly expressed β-lactamase encoded by the vector ampicillin resistance marker.

**Table IX: Expression of *trans*-feruloyl SCoA hydratase/aldol cleavage enzyme in *Escherichia coli*.**

Enzyme was extracted as described in Example 2 and activity determined as described in Example 4, using *trans*-feruloyl SCoA (0.28mM) and HMPHP SCoA (0.4mM)) as substrates. Reaction mixtures contained *ca.* 10 $\mu$ g of protein.

n.d. - not detectable

<i>E. coli</i> Cell line	Specific activity (nkat/mg of protein)					
	<i>trans</i> -Feruloyl SCoA as substrate			HMPHP SCoA as substrate		
	Vanillin formation	Acetyl SCoA formation	Vanillin formation	Acetyl SCoA formation	Feruloyl SCoA formation	Feruloyl SCoA formation
Control	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
Control (induced)	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
1039	1.53	1.80	1.52	1.80	3.35	3.35
1039 (induced)	1.24	1.34	1.27	1.46	3.16	3.16

The DNA downstream of the gene encoding the 31kD protein was targeted for cloning and sequencing and for analysis of additional open reading frames. A PCR-generated probe was used to identify an overlapping *Xho*I fragment of 1.5 kb. Sequencing from this fragment and subsequently  
5 directly from the parent cosmid clone pFI794 revealed a second open reading frame of 1449 bp beginning at base 3804. The translation of this nucleotide sequence revealed a polypeptide of 483 amino acids. Comparison with sequences in the databases revealed appreciable homology to salicylaldehyde: NAD<sup>+</sup> oxidoreductase.

10

In order to confirm the function of this gene, expression was determined in *E. coli* strain DH5, which contained the vector pUC18 into which the full-length open reading frame had been inserted such that expression was from the lac promoter on the vector. Vanillin: NAD<sup>+</sup> oxidoreductase  
15 activity was confirmed and was absent from a control strain bearing the unmodified pUC 18 vector. Using the enzyme assay described in Example 2, activity with vanillin as substrate was determined as 3.0 nkat/mg of protein; activity with salicylaldehyde was 2.8 nkat/mg.

20 Additional sequence analysis of DNA cloned from *Ps. fluorescens* AN103 was undertaken using cosmid clone pFI 793. The 1.8, 0.9 and 0.8 kb EcoRI/PstI fragments were sub-cloned into *E. coli* vector pUC18 and their nucleotide sequences were determined. Sequencing the 0.9 kb sub-clones revealed that there are two different fragments of the same size. The  
25 nucleotide sequences of DNA fragments of 1837bp, 960bp, 959bp and 854bp in sub-clones pFI 901, pFI 912, pFI 913 and pFI 911 respectively are presented in Figures 13 to 16. Outward reading PCR primers were designed from the ends of each of the four sequences as shown in Figure

17. Use of these primers in all possible pairwise combination with pFI 793 as template showed that the 1.8 kb fragment of pFI 901 was separated from the 959bp fragment of pFI 913 by 1.5 kb on the cosmid DNA (Figure 18). Direct sequence analysis of this 1.5 kb PCR product enabled  
5 this together with the 1.8 kb and 959bp fragments to be merged into one larger fragment of 4.3 kb (Figure 19).

**Example 6: Production of vanillin from *trans*-feruloyl SCoA and enzyme activities II and III**

10

*Trans*-feruloyl SCoA was synthesised as described in Example 2, and was used as a substrate of the *trans*-feruloyl SCoA hydratase/aldol cleavage enzyme (ie a single polypeptide with enzyme activities II and III) as purified by the method described in Example 4. Vanillin was produced  
15 from *trans*-feruloyl SCoA.

**Example 7: A transgenic tobacco plant which produces vanillin**

*Nicotiana tabacum* (tobacco) is transformed using a strain of  
20 *Agrobacterium tumefaciens* which has been modified so that it transfers the *Ps. fluorescens* gene encoding enzyme activities II and III (see Example 5) to the tobacco plant. The tobacco plant produces vanillin in those parts of the plant which have *trans*-feruloyl SCoA present, at least in the form of a vanillin glycoside.

25



**CLAIMS**

1. A method of producing vanillin comprising the steps of
  - 5 (1) providing *trans*-ferulic acid or a salt thereof; and
  - (2) providing *trans*-ferulate:CoASH ligase activity (enzyme activity I), *trans*-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl-S-CoA (HMPHP SCoA) cleavage activity (enzyme  
10 activity III).
2. A method according to Claim 1 wherein means for converting vanillin to a non-vanillin product is absent or reduced.
- 15 3. A method according to Claim 1 wherein the enzyme activities I, II and III are provided by *Pseudomonas fluorescens* biovar. V, strain AN103 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof.
- 20 4. A method according to any one of Claims 1 to 3 wherein the enzyme activities I, II and III are provided by an intact-cell-free system of *Pseudomonas fluorescens* biovar. V, strain AN103 as deposited under the Budapest Treaty at the National Collections of  
25 Industrial and Marine Bacteria Limited, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof.

5. A method according to Claim 2 wherein means for converting vanillin to a non-vanillin product is an activity that interconverts vanillin and vanillic acid (enzyme activity IV).
- 5 6. A method according to Claim 5 wherein  $\text{NAD}^+$  is absent.
7. A method according to Claim 1 or 2 further comprising the step of
  - (3) providing any one of the cofactors Coenzyme ASH, ATP or  
10  $\text{Mg}^{2+}$ , or other functionally equivalent cofactors.
8. A method according to Claim 7 wherein either one of the cofactors Coenzyme ASH and ATP is recycled or generated.
- 15 9. A method according to Claim 8 wherein Coenzyme ASH is recycled using the enzymes citrate synthase and citrate lyase.
10. A method according to Claim 8 wherein ATP is generated using the enzymes-adenylate kinase and acetate kinase.  
20
11. A method according to any one of Claims 1 to 10 wherein the *trans*-ferulic acid or salt thereof is provided by action of *trans*-ferulic acid esterase on plant material, said plant material containing an ester of *trans*-ferulic acid.  
25
12. A method according to any one of Claims 1 to 11 wherein at least one of the enzyme activities II or III is provided by a substantially purified enzyme.

13. A method according to any one of Claims 1 to 12 further comprising the step of providing a compound other than *trans*-ferulic acid or a salt thereof which may be converted by any one of enzyme activities I, II or III into a desirable product.
- 5
14. A method according to Claim 13 wherein said compound is any of *trans*-4-coumaric acid or a salt thereof, *trans*-4-coumaroyl S CoA, *trans*-caffeic acid or a salt thereof, *trans*-caffeoyl SCoA or 3,4-methylene dioxy-*trans*-cinnamic acid or a salt thereof.
- 10
15. A method according to Claim 14 wherein said compound is *trans*-4-coumaric acid or a salt thereof or *trans*-4-coumaroyl SCoA.
- 15
16. A method of producing vanillic acid, or a salt thereof, comprising the steps as defined in any one of Claims 1, 3, 4 and 7 to 12 and the further step of providing enzyme activity IV.
- 20
17. A method according to any one of Claims 1 to 12 comprising the further step of separating vanillin from the other reaction components.
- 25
18. A method according to Claim 16 comprising the further step of separating vanillic acid, or a salt thereof, from the other reaction components.
19. *Pseudomonas fluorescens* biovar V, strain AN103 as deposited under the Budapest Treaty at the National Collections of Industrial

and Marine Bacteria Limited, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof.

20. A mutant of *Pseudomonas fluorescens* biovar V, strain AN103  
5 according to Claim 18 which accumulates vanillin when provided with *trans*-ferulic acid or a salt thereof.
21. A polypeptide which, in the presence of appropriate cofactors if  
any, is capable of catalysing the interconversion of *trans*-feruloyl  
10 SCoA and 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionylSCoA (HMPHP SCoA).
22. A polypeptide according to Claim 21 which is a *trans*-feruloyl S  
CoA hydratase.
- 15 23. A polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of 4-hydroxy-3-methoxyphenyl- $\beta$ -hydroxy-propionyl SCoA (HMPHP SCoA) and vanillin.
- 20 24. A polypeptide according to Claim 23 which is a HMPHP SCoA cleavage enzyme.
- 25 25. A polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of *trans*-feruloyl-S-CoA and vanillin *via* HMPHP SCoA.

26. A polypeptide according to any one of Claims 21, 23 and 25 comprising the amino acid sequence

MetSerThrTyrGluGlyArgTrpLysThrValLysValGluIleGluAspGlyIleAla  
 5 PheValIleLeuAsnArgProGluLysArgAsnAlaMetSerProThrLeuAsnArgGlu  
 MetIleAspValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuThr  
 GlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheArgGluValAsp  
 AlaGlyProGluIleLeuGlnGluLysIleArgArgGluAlaSerGlnTrpGlnTrpLys  
 LeuLeuArgMetTyrAlaLysProThrIleAlaMetValAsnGlyTrpCysPheGlyGly  
 10 GlyPheSerProLeuValAlaCysAspLeuAlaIleCysAlaAspGluAlaThrPheGly  
 LeuSerGluIleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAsp  
 ThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrPheGlyGlyGln  
 LysAlaAlaGluMetGlyLeuValAsnGluSerValProLeuAlaGlnLeuArgGluVal  
 ThrIleGluLeuAlaArgAsnLeuLeuGluLysAsnProValValLeuArgAlaAlaLys  
 15 HisGlyPheLysArgCysArgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAla  
 LysLeuAspGlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGln  
 PheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArg

(SEQ ID No 2) or a fragment or variant thereof.

20

27. A vanillin:NAD<sup>+</sup> oxidoreductase comprising the amino acid sequence

MetLeuAspValProLeuLeuIleGlyGlyGlnSerCysProAlaArgAspGlyArgThr  
 PheGluArgArgAsnProValThrGlyGluLeuValSerArgValAlaAlaAlaThrLeu  
 25 GluAspAlaAspAlaAlaValAlaAlaAlaGlnGlnAlaPheProAlaTrpAlaAlaLeu  
 AlaProAsnGluArgArgSerArgLeuLeuLysAlaAlaGluGlnLeuGlnAlaArgSer  
 GlyGluPheIleGluAlaAlaGlyGluThrGlyAlaMetAlaAsnTrpTyrGlyPheAsn  
 ValArgLeuAlaAlaAsnMetLeuArgGluAlaAlaSerMetThrThrGlnValAsnGly

GluValIleProSerAspValProGlySerPheAlaMetAlaLeuArgGlnProCysGly  
 ValValLeuGlyIleAlaProTrpAsnAlaProValIleLeuAlaThrArgAlaIleAla  
 MetProLeuAlaCysGlyAsnThrValValLeuLysAlaSerGluLeuSerProAlaVal  
 HisArgLeuIleGlyGlnValLeuGlnAspAlaGlyLeuGlyAspGlyValValAsnVal  
 5 IleSerAsnAlaProAlaAspAlaAlaGlnIleValGluArgLeuIleAlaAsnProAla  
 ValArgArgValAsnPheThrGlySerThrHisValGlyArgIleValGlyGluLeuSer  
 AlaArgHisLeuLysProAlaLeuLeuGluLeuGlyGlyLysAlaProLeuLeuValLeu  
 AspAspAlaAspLeuGluAlaAlaValGlnAlaAlaAlaPheGlyAlaTyrPheAsnGln  
 GlyGlnIleCysMetSerThrGluArgLeuIleValAspAlaLysValAlaAspAlaPhe  
 10 ValAlaGlnLeuAlaAlaLysValGluThrLeuArgAlaGlyAspProAlaAspProGlu  
 SerValLeuGlySerLeuValAspAlaSerAlaGlyThrArgIleLysAlaLeuIleAsp  
 AspAlaValAlaLysGlyAlaArgLeuValIleGlyGlyGlnLeuGluGlySerIleLeu  
 GlnProThrLeuLeuAspGlyValAspAlaSerMetArgLeuTyrArgGluGluSerPhe  
 GlyProValAlaValValLeuArgGlyGluGlyGluGluAlaLeuLeuGlnLeuAlaAsn  
 15 AspSerGluPheGlyLeuSerAlaAlaIlePheSerArgAspThrGlyArgAlaLeuAla  
 LeuAlaGlnArgValGluSerGlyIleCysHisIleAsnGlyProThrValHisAspGlu  
 AlaGlnMetProPheGlyGlyValLysSerSerGlyTyrGlySerPheGlyGlyLysAla  
 SerIleGluHisPheThrGlnLeuArgTrpValThrLeuGlnAsnGlyProArgHisTyr  
 ProIle

20

(SEQ ID No 4) or a fragment or variant thereof.

28. A polypeptide as defined in any one of Claims 21 to 27 which is substantially pure.

25

29. A polynucleotide encoding a polypeptide as defined in any one of Claims 21 to 27.

30. A polynucleotide comprising at least a part of the *Pseudomonas fluorescens* DNA contained within the cosmid clone pFI 793 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, Scotland under Accession No NCIMB 40777, or a fragment or variant thereof.
31. Cosmid pFI 793 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, Scotland under Accession No NCIMB 40779.
32. A polynucleotide according to Claim 30 encoding a polypeptide as defined in any one of Claims 21 to 27.
33. A polynucleotide according to any one of Claims 29, 30 or 32 comprising the nucleotide sequence
- ATGAGCACATACGAAGGTCGCTGGAAAACGGTCAAGGTCGAAATCGAAGACGGCATCGCG  
 TTTGTCATCCTCAATCGCCCGGAAAAACGCAACGCGATGAGCCCGACCCTGAACCGCGAG  
 ATGATCGATGTTCTGGAAACCCTCGAGCAGGACCCTGCCGCCGGTGTGCTGGTGCTGACC  
 GGTGCGGGCGAAGCCTGGACCGCAGGCATGGACCTCAAGGAATACTTCCGCGAAGTGAG  
 GCCGGCCCGGAAATCCTCCAGGAAAAAATCCGCCGGAAGCCTCGCAATGGCAATGGAAA  
 CTGCTGCGCATGTACGCCAAGCCGACCATCGCCATGGTCAATGGCTGGTGCTTCGGCGGC  
 GGTTTCAGCCCGCTGGTGGCCTGCGACCTGGCGATCTGCGCCGACGAAGCAACCTTCGGT  
 CTCTCGGAAATCAACTGGGGTATCCCGCCGGGCAACCTGGTGAGCAAGGCCATGGCCGAC  
 ACCGTGGGGCCACCGCCAGTCGCTCTACTACATCATGACCGGCAAGACCTTCGGTGGGCAG  
 AAAGCCCGCGAGATGGGCCTGGTCAACGAAAGCGTGCCCTGGCGCAACTGCGCGAAGTC  
 ACCATCGAGCTGGCGCGTAACCTGCTCGAAAAAAACCCGGTGGTGCTGCGTGCCGCCAAA  
 CACGGTTTCAAACGCTGCCGCGAACTGACCTGGGAGCAGAACGAGGATTACCTGTACGCC  
 AAGCTCGATCAGTCGCGTTTGCTGGACACCGAAGGCGGTGCGGAGCAGGGCATGAAGCAA

TTCTCTGACGACAAGAGCATCAAGCCTGGCCTGCAAGCGTATAAACGC

(SEQ ID No 1) or a fragment or variant thereof.

- 5 34. A polynucleotide according to any one of Claims 29, 30 or 32 comprising the nucleotide sequence

ATGCTGGACGTGCCCCCTGCTGATTGGCGGCCAGTCGTGCCCCGCGCGACGGTCGAACC  
TTCGAGCGCCGCAACCCGGTGA CTGGCGAGTTGGTGTCTCGCGGGTTGCCGCCGCCACCCCTG  
GAAGATGCCGACGCCGCCGTGGCCGCTGCCAGCAAGCGTTTCCCGCGTGGGCCGCGCTG  
10 GCGCCCAATGAACGGCGCAGCCGTTTGCTCAAGGCCGCCGAACAATTGCAGGCGCGCAGC  
GGCGAGTTCATCGAGGCGGCGGGCGAGACCGGCCCATGGCCA ACTGGTACGGGTTCAAC  
GTACGGCTGGCGGCCAACATGCTGCGTGAAGCGGCATCGATGACCACCCAGGTCAATGGT  
GAAGTGATTCCCTCGGACGTTCCCGGCAGTTTCGCCATGGCCCTGCGCCAGCCCTGTGGC  
GTGGTGCTGGGCATCGCCCCCTGGAACGCCCCGGTGATTCTCGCCACCCGGGCGATTGCC  
15 ATGCCGCTGGCCTGTGGCAACACCGTGGTGCTGAAGGCTTCCGAGCTGAGTCCGGCGGTG  
CATCGCTTGATCGGCCAGGTGCTGCAGGACGCCGGCCTGGGCGATGGCGTGGTCAACGTC  
ATCAGTAATGCGCCGGCGGATGCGGCACAGATTGTCTGAGCGCCTGATTGCCAACCCGGCC  
GTACGCCGGGTCAATTTACCCGTTTCGACCCACGTCCGGCGCATTGTCCGGCGAGCTCTCG  
GCGGCCACCTCAAACCGGCGTTGCTCGAGCTGGGCGGCAAGGCACCGTTGCTGGTGCTC  
20 GACGATGCCGACCTGGAGGCTGCCGTGCAGGCGGCGCGTTTGGCGCCTACTTCAACCAG  
GGACAGATCTGTATGTCCACCGAGCGCCTGATTGTCTGATGCCAAGGTGGCCGACGCCTTT  
GTCGCCCAGTTGGCGGCCAAGGTCGAGACCCTGCGCGCCGGTGATCCTGCCGACCCGGAG  
TCGGTGCTCGGTTCTGCTGGTGGACGCCAGCGCTGGCACGCGGATCAAAGCGTTGATCGAT  
GATGCCGTGGCCAAGGGCGCGCGCCTGGTAATCGGCGGGCAACTGGAGGGCAGCATCTTG  
25 CAGCCGACCCTGCTCGACGGTGTCTGACGCGAGCATGCGTTTGTACCGGAAGAGTCCTTC  
GGCCCCGGTGGCGGTGGTGCTGCGCGGCGAGGGCGAAGAAGCGCTGTTGCAACTGGCCAAC  
GACTCCGAGTTCGGTTTGTCTGGCGGCGATTTCAGTCGTGACACCGGCCGTGCCCTGGCC  
CTGGCCCAGCGGGTCTGAATCGGGCATCTGCCACATCAACGGCCCCGACCGTGCACGACGAA



GCGCAAATGCCTTTTGGCGGGGTCAAGTCCAGCGGCTACGGCAGTTTTGGCGGCAAGGCA  
TCGATTGAGCATTTCACCTCAGTTGCGCTGGGTCAACCCTCCAGAATGGTCCACGGCACTAT  
CCGATC

- 5 (SEQ ID No 3) or a fragment or variant thereof.
35. A nucleic acid vector comprising a polynucleotide according to any one of Claims 28 to 34.
- 10 36. A host cell comprising a polynucleotide as defined in any one of Claims 28 to 34.
37. A host cell according to Claim 36 comprising nucleic acid which encodes any one of the polypeptides as defined in Claims 21, 23  
15 and 27.
38. A host cell according to Claim 36 or 37 which is a bacterium or yeast.
- 20 39. A host cell according to Claim 38 which is a food-grade bacterium or yeast.
40. A host cell according to Claim 39 which is a *Lactococcus* spp. or a *Lactobacillus* spp. or *Saccharomyces cerevisiae* or a biovar  
25 thereof.
41. A host cell according to Claim 37 which is a plant cell.

42. A host cell according to Claim 41 wherein said plant cell is a cell from any one of *Nicotiana* spp., *Solanum tuberosum*, *Brassica* spp., *Beta* spp., *Capsicum* spp. and *Vanilla* spp.
- 5 43. A host cell according to Claim 41 or 42 wherein said cell is comprised in a plant.
44. A transgenic plant comprising at least one polynucleotide according to Claim 29 and which, as a consequence of the presence of said polynucleotide, expresses any of the enzyme activities II and III.
- 10
45. A transgenic plant according to Claim 45 which, as a consequence of the presence of said polynucleotides, expresses the enzyme activities II and III.
- 15
46. A transgenic plant according to Claim 44 or 45 wherein said plant is selected from *Nicotiana* spp., *Solanum tuberosum*, *Brassica* spp., *Beta* spp., *Capsicum* spp. and *Vanilla* spp.
- 20 47. A method according to Claims 1 to 18 wherein the enzyme activities II and III are provided by the host cell according to any of Claims 36 to 43 or a transgenic plant according to any one of Claims 44 to 46, or an extract thereof.
- 25 48. A method according to Claims 1 to 18 wherein the enzyme activities I, II and III are provided by a microorganism which can convert *trans*-ferulic acid to vanillin.


49. Use of *Pseudomonas fluorescens* biovar. V, strain AN103 or a mutant or derivative thereof for producing vanillin, or vanillic acid or salt thereof.
- 5 50. Use of a polypeptide according to any one of Claims 21 to 28 for producing vanillin, or vanillic acid or salt thereof.
51. Use of a polynucleotide according to any one of Claims 29 to 35 for producing vanillin, or vanillic acid or salt thereof.
- 10 52. Use of a host cell according to any one of Claims 36 to 43 for producing vanillin, or vanillic acid or salt thereof.
- 15 53. Use of a transgenic plant according to any one of Claims 44 to 46 for producing vanillin, or vanillic acid or salt thereof.
54. Use of *Pseudomonas fluorescens* biovar V, strain AN103 or a mutant or derivative thereof for converting a compound, other than *trans*-ferulic acid or a salt thereof, into a desirable product.
- 20 55. Use of a polypeptide according to any one of Claims 21 to 28 for converting a compound into a desirable product.
- 25 56. Use of a polynucleotide according to any one of Claims 29 to 35 for converting a compound into a desirable product.
57. Use of a host cell according to any one of Claims 36 to 43 for converting a compound into a desirable product.

58. Use of a transgenic plant according to any one of Claims 44 to 46 for converting a compound, other than *trans*-ferulic acid or a salt thereof, into a desirable product.
- 5 59. Use according to any one of Claims 54 to 58 wherein said desirable product is a flavour or aroma.
60. Use according to Claims 54 to 59 wherein said compound is any one of *trans*-4-coumaroyl S CoA and *trans*-caffeoyl SCoA.
- 10 61. A food or beverage comprising a host cell according to any one of Claims 36 to 43, or an extract thereof.
62. A food or beverage comprising a transgenic plant according to  
15 Claim 44 to 46, or a part or extract thereof.
63. A method of producing vanillin comprising
- (1) providing *trans*-feruloyl SCoA; and
- 20 (2) providing *trans*-feruloyl SCoA hydratase activity (enzyme activity II), and HMPHP SCoA cleavage activity (enzyme activity III).
- 25 64. Any novel method of producing vanillin or vanillic acid substantially as disclosed herein.
65. Any novel polypeptide substantially as disclosed herein.

66. Any novel polynucleotide substantially as disclosed herein.

1/27

# Vanillin Pathway in *Pseudomonas fluorescens*, biovar V, strain AN103



**Figure 1**  
**SUBSTITUTE SHEET (RULE 26)**

2/27




Figure 2

3/27




Figure 3



- 4/27




Figure 4

5/27




Figure 5

6/27




Figure 6

7/27





Figure 7

WO 97/35999

PCT/GB97/00809

8/27

Fig 8.




97.4 kDa	Phosphorylase b
66.2 kDa	Bovine serum albumin
45.5. kDa	Hen egg white ovalbumin
31.0 kDa	Bovine carbonic anhydrase
21.5 kDa	Soybean trypsin inhibitor
14.4. kDa	Hen egg white lysozyme

WO 97/35999

PCT/GB97/00809

9/27

EcoRI/PstI digests of cosmid clones

Agarose gel

Figure 9

Redundant primers designed from 20 N-terminal amino acid sequence

10/27

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Ser	Thr	Tyr	Glu	Gly	Arg	Trp	Lys	Thr	Val	Lys	Val	Glu	Ile	Gln	Asp	Gly	Ile	Ala	Phe
Primer P66										Primer P67									
TCC	ACG	TAC	GAG	GGC	CGC	TGG	AAG	ACG	GTC	AAG	GTC	GAG	ATC	CAG	GAC	GGC	ATC	GCG	TTT
GG	C	T	A	T	G	G	A	C	G	A	G	A	T	A	T	T	T	C	C

Figure 10

SUBSTITUTE SHEET (RULE 26)

WO 97/35999

PCT/GB97/00809

11/27




Figure 11



12/27

Nucleotide and amino acid sequence of the cleavage enzyme and vanillin dehydrogenase.  
Sequence determined from sub-cloned fragments pFI989 and pFI1056 and from the cosmid  
clone pFI794

1	GAATTCTCTCGCGCTTTGCCAGTCCTACCCGCTGGTGCAGATCGAGGTG	50
51	CATTGCGAGTCGTCCAAGCAACTTCTCTTGCGCCAGGACCTCGACCTGTC	100
101	CATCGTGACCCGCGAACCCGGCAACGAAATCGGCCAGCTGTTGCGCAAGG	150
151	AGCGTTTTGTCTGGGCCCAGGCCAGTGCTACAACCCTGTCGAGCAATCA	200
201	CCCTTGCCGCTGGCGATGTTCAACAGTGACTGCTTCTGCCGTCTTTGGGC	250
251	CTGTAATGCGCTGGATGCCGCCGACGTGAATACCGCATCGCCTACAACA	300
301	GTTTCGAGCCTGTTCGGCGCTGATGGCAGTGGTCAGCGCCGGGCTGGCGGTG	350
351	ACCGCTCAATTGGAAAGCCTGATCCCGCAGGACATGCGCATCCTCGGCGA	400
401	GGCCGAAGGCCTGCCCCAACTGCCCAGGCGAGCATCATGCTGCTGCGCA	450
451	ATCTGCATAATCCGTCGCCGATTACCGAATGTCTGGCGGAGCACATCGTC	500
501	GAAGGCTTCAAACCTTTAAAGGCGAGCATCACCGCGCAGAGCACCAGAAAA	550
551	CCGCAGAACAAACCGCGTAGTAGCCGCTCCGGCAGGGCGTGGGCAATCTT	600
601	CACGCCCCAACTGATACTGAGCAGACCGCCCACCGCCATGGGCAACGCGA	650
651	TGTGCCAGTCGACTTGCTGGTGCAGGGCGTAGGTCGCCAGGGTTACACCG	700
701	GTGCTGGGTAAAGCCAGTGCCAACGACAGGCCCTGGGCCACCACCTGGGT	750
751	GGTGCCAAACAAGCTGGTCAATACCGGCGTTGCGACCACAGCGCCGCCCA	800
801	CCCCGAACAAGCCACCCATGACGCCGGACGCCGCGCCAGCACCCCGAGC	850
851	CAGGGCCACGAATAGCGCATCTGCGCAGTCGGTGCCGCCGAGTCATGAA	900
901	CATGCGCATCAGGTTGTAGACCGACAAGGCCACCAGAAACACCACGAACC	950
951	CGATGCGCATCACCTGAGCGTCGATCCCCACCGCCCAGATCGAACCGAGC	1000
1001	CAGGCAAAGCAGAACCCCATGGAGGCCAACGGCAGCGCGTGGCGCAACTC	1050
1051	GATGCGATTACGTTGGTGATAACGCCATAACGCCAGCATCACGTTTCGGCA	1100
1101	CCACCATGACCAGAGCTGTGCCCTGGGCAAGCTGCTGATCCAGGCCAAAT	1150
1151	AACACGCCCAGAGCGGGAATGGCGATCAAGCCACCGCCGATTCCAAACAA	1200
1201	ACCACCTACGGTCCCCAAGGCTGCACCGAGCAGCAGGTACATCGTCAACT	1250
1251	CAATCACAGGTCAAATTCCTCACGTCAATGGGTGCATCCTACGCAGTCG	1300

Figure 12 (Part 1 of 5)

WO 97/35999

PCT/GB97/00809

13/27

1301	GGGCTAGCGGGGAAACGCACAGCAACGCACAATGGCTATGCCAAATTCGC	1350
1351	ACAAGCAATCCTCCATGAACCCACACGCTCACCAGATCAATTGGGTCTA	1400
1401	TTCCTTGATGTCGTGGAAACCGGCAGTTTTTCCGCTGCGTCCCGACGCCA	1450
1451	TCCGCTGACACCCCTCCGCCGTCGCCAGGCGTATCGATAGTCTGGAACAGG	1500
1501	CGCTCGACAGCCAATTGTTTCGTGCGCACCACCTCATGCTGTGCGTCTTACG	1550
1551	CCAGCGGGATTGGCGTTTGCCGAGCGAGCCCGACGCATTGTGGCGAGTT	1600
1601	GCGCCTGGCGGGGCGAGGTCGCCTCCCTGAGCAGCGCGCTGAAGGAC	1650
1651	TGATTCGGGTCGACGCCCCCGCAGCCTTCGGCCGAGGCACCTGGCGCCG	1700
1701	GTGATCTATGACTACGACTTCGCCGCCCTCCGGCGTGCCCGGGCTGCGGGG	1750
1751	CCGTTTTCGCTACCTGCGCGGCGACAACATCGAGTTGAAAGCCTTCAACG	1800
1801	CCGAAGACCGCAAGGAGCGCGAGTTCCAGATGGAGCTGGGCTACGTGGTG	1850
1851	CAAAGCGGTCCGCTGAAAAACGTCCGCCCTGGTGGCGCGCAAGGCAATCTA	1900
1901	CCGCAATGACTTCCCCACTGGCGCCGCCTTCCGCGATGAAAACCAGACGC	1950
1951	GGTTTCTGGTGACCTATACCTTGCCGATCTGGTGAGTGCGCGTGTTCGGG	2000
2001	TGGGGCTGATGGCCCCATCGCGAGCGGGCTCGCTCCTACAGTGGGTTTGG	2050
2051	TGTTAATCACAGAGGCTGTGGAGCTTGCAGCCCCCTGTAGGCGCTGGCTTG	2100
2101	CCAGCGAGGCGTAGGCACTGCTGGCGCAAGGCTCAAGGCCCCACAGGCCC	2150
2151	GCTCCCACCCTTCAGATTTTCTATTCCCTGATAAATCTTCTTCAGCAGCCG	2200
2201	CAGCAGCTCGTCGCGTTCCTGGTCGTCCAGTGCCGAGGTGGCGTCGAGGT	2250
2251	CGCTTTGGGCGGCGATCTGGTTCAGTTCCTTGAGCAGGGTCTCGCCGGTC	2300
2301	TTGCTGAGGAATATCCCGTACGAGCGCTTGTCCGGCTTGCAGCGCACACG	2350
2351	CACCGCCAGCGCCCGGCTTTCCAGCTTATTTCAGCAGCGGTACCACCTGGG	2400
2401	GCGGCTCGATGCTCAGAGCCCGGGCCAGGTCGGCCTGCATCAGGCCGGGG	2450
2451	TTCTGATTGATGATCGCCAGCGCCGAGAATTGCGCGGGGCGCAGATCGTG	2500
2501	GGCCGAGAGGCGGCTGATCAGGTTCTGGAACAGTTTCAGTTGCGCACGGC	2550
2551	GCATGGCGTAGCCGATCAGATCATTCAGCGCCGAATCCATGGGCGCCTGG	2600
2601	GTCTCGGCGGGAGTCGACGCAGCCTCGACCGACTCGGCGAGGGGGGAGGG	2650
2651	CTTGGCCATTGCGGGGAAGTCCTGAAGATGGAGGTTAACAAGACTATCTA	2700
2701	GTTTGCCGACCTTGGCCGGTGATTGCTACGGCCAATATCGCTCGGCGCCA	2750

Figure 12 (Part 2 of 5)

SUBSTITUTE SHEET (RULE 26)

14/27

2751	AGACCGACCAGTCCATCACCTGCGAGAAAATTGGTTAAATCAATTAATAG	2800
2801	TTAATTGACATAACTAATTCGCTGCTTTAATTTTCGAGTCATCTTCAAAAC	2850
2851	CCAGAACAAGAGAGCATCGCCATGAGCACATACGAAGGTCGCTGGAAAAC MetSerThrTyrGluGlyArgTrpLysTh	2900
2901	GGTCAAGGTCGAAATCGAAGACGGCATCGCGTTTGTTCATCCTCAATCGCC rValLysValGluIleGluAspGlyIleAlaPheValIleLeuAsnArgP	2950
2951	CGGAAAAACGCAACGCGATGAGCCCCGACCCTGAACCGCGAGATGATCGAT roGluLysArgAsnAlaMetSerProThrLeuAsnArgGluMetIleAsp	3000
3001	GTTCTGGAAACCCTCGAGCAGGACCCTGCGCGCGGTGTGCTGGTGCTGAC ValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuTh	3050
3051	CGGTGCGGGCGAAGCCTGGACCGCAGGCATGGACCTCAAGGAATACTTCC rGlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheA	3100
3101	GCGAAGTGGACGCGCGCCCGGAAATCCTCCAGGAAAAAATCCGCGCGGAA rgGluValAspAlaGlyProGluIleLeuGlnGluLysIleArgArgGlu	3150
3151	GCCTCGCAATGGCAATGGAAACTGCTGCGCATGTACGCCAAGCCGACCAT AlaSerGlnTrpGlnTrpLysLeuLeuArgMetTyrAlaLysProThrIl	3200
3201	CGCCATGGTCAATGGCTGGTGCTTCGGCGGCGGTTTCAGCCCGCTGGTGG eAlaMetValAsnGlyTrpCysPheGlyGlyGlyPheSerProLeuValA	3250
3251	CCTGCGACCTGGCGATCTGCGCCGACGAAGCAACCTTCGGTCTCTCGGAA laCysAspLeuAlaIleCysAlaAspGluAlaThrPheGlyLeuSerGlu	3300
3301	ATCAACTGGGGTATCCCGCCGGGCAACCTGGTGAGCAAGGCCATGGCCGA IleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAs	3350
3351	CACCGTGGGCCACCGCCAGTCGCTCTACTACATCATGACCGCAAGACCT pThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrP	3400
3401	TCGGTGGGCAGAAAGCCGCGGAGATGGGCCTGGTCAACGAAAGCGTGCCC heGlyGlyGlnLysAlaAlaGluMetGlyLeuValAsnGluSerValPro	3450
3451	CTGGCGCAACTGCGCGAAGTCACCATCGAGCTGGCGCGTAACCTGCTCGA LeuAlaGlnLeuArgGluValThrIleGluLeuAlaArgAsnLeuLeuGl	3500
3501	AAAAAACCCGGTGGTGCTGCGTGCCGCCAAACACGGTTTCAAACGCTGCC uLysAsnProValValLeuArgAlaAlaLysHisGlyPheLysArgCysA	3550
3551	GCGAACTGACCTGGGAGCAGAACGAGGATTACCTGTACGCCAAGCTCGAT rgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAlaLysLeuAsp	3600
3601	CAGTCGCGTTTGTCTGGACACCGAAGGCGGTGCGGAGCAGGGCATGAAGCA GlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGl	3650
3651	ATTCCTCGACGACAAGAGCATCAAGCCTGGCCTGCAAGCGTATAAACGCT nPheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArgE	3700
3701	GAAGGACGACGCTGCGGGCGCATTGCGCGAAGGCGAGTGCGCCCTGAAGC nd	3750

Figure 12 (Part 3 of 5)

15/27

3751	TGCGTTTACATCACTGCTAAGCATTCGGATAAAGACGATAAAGAGGAATC	3800
3801	ACCATGCTGGACGTGCCCCCTGCTGATTGGCGGCCAGTCGTGCCCCGCGCG MetLeuAspValProLeuLeuIleGlyGlyGlnSerCysProAlaAr	3850
3851	CGACGGTCGAACCTTCGAGCGCCGCAACCCGGTGA CTGGCGAGTTGGTGT gAspGlyArgThrPheGluArgArgAsnProValThrGlyGluLeuValS	3900
3901	CGCGGGTTGCCGCCGCCACCCTGGAAGATGCCGACGCCGCCGTGGCCGCT erArgValAlaAlaAlaThrLeuGluAspAlaAspAlaAlaValAlaAla	3950
3951	GCCCAGCAAGCGTTTCCCGCGTGGGCGCGCTGGCGCCCAATGAACGGCG AlaGlnGlnAlaPheProAlaTrpAlaAlaLeuAlaProAsnGluArgAr	4000
4001	CAGCCGTTTGCTCAAGGCCGCCGAACAATTGCAGGCGCGCAGCGGCGAGT gSerArgLeuLeuLysAlaAlaGluGlnLeuGlnAlaArgSerGlyGluP	4050
4051	TCATCGAGGCGGCGGGCGAGACCGCGCCATGGCCA ACTGGTACGGGTTC heIleGluAlaAlaGlyGluThrGlyAlaMetAlaAsnTrpTyrGlyPhe	4100
4101	AACGTACGGCTGGCGGCCAACATGCTGCGTGAAGCGGCATCGATGACCAC AsnValArgLeuAlaAlaAsnMetLeuArgGluAlaAlaSerMetThrTh	4150
4151	CCAGGTCAATGGTGAAGTGATTCCCTCGGACGTTCCCGGCAGTTTCGCCA rGlnValAsnGlyGluValIleProSerAspValProGlySerPheAlaM	4200
4201	TGGCCCTGCGCCAGCCCTGTGGCGTGGTGTGGGCATCGCCCCCTGGAAC etAlaLeuArgGlnProCysGlyValValLeuGlyIleAlaProTrpAsn	4250
4251	GCCCCGGTGATTCTCGCCACCCGGGCGATTGCCATGCCGCTGGCCTGTGG AlaProValIleLeuAlaThrArgAlaIleAlaMetProLeuAlaCysGl	4300
4301	CAACACCGTGGTGTGAAGGCTTCCGAGCTGAGTCCGGCGGTGCATCGCT yAsnThrValValLeuLysAlaSerGluLeuSerProAlaValHisArgL	4350
4351	TGATCGGCCAGGTGCTGCAGGACGCCGGCCTGGGCGATGGCGTGGTCAAC euIleGlyGlnValLeuGlnAspAlaGlyLeuGlyAspGlyValValAsn	4400
4401	GTCATCAGTAATGCGCCGGCGGATGCGGCACAGATTGTGAGCGCCTGAT ValIleSerAsnAlaProAlaAspAlaAlaGlnIleValGluArgLeuIl	4450
4451	TGCCAACCCGGCCGTACGCCGGGTCAATTTACCGGTTTCGACCCACGTCG eAlaAsnProAlaValArgArgValAsnPheThrGlySerThrHisValG	4500
4501	GGCGCATTTGTCGGCGAGCTCTCGGCGCGCCACCTCAAACCGGCGTTGCTC lyArgIleValGlyGluLeuSerAlaArgHisLeuLysProAlaLeuLeu	4550
4551	GAGCTGGGCGGCAAGGCACCGTTGCTGGTGTGCTCGACGATGCCGACCTGGA GluLeuGlyGlyLysAlaProLeuLeuValLeuAspAspAlaAspLeuGl	4600
4601	GGCTGCCGTGCAGGCGGCGGCGTTTGGCGCCTACTTCAACCAGGGACAGA uAlaAlaValGlnAlaAlaAlaPheGlyAlaTyrPheAsnGlnGlyGlnI	4650
4651	TCTGTATGTCCACCGAGCGCCTGATTGTGATGCCAAGGTGGCCGACGCC leCysMetSerThrGluArgLeuIleValAspAlaLysValAlaAspAla	4700

**Figure 12 (Part 4 of 5)**  
**SUBSTITUTE SHEET (RULE 26)**

16/27

4701	TTTGTGCGCCAGTTGGCGGCCAAGGTCGAGACCCTGCGCGCCGGTGATCC	4750
	PheValAlaGlnLeuAlaAlaLysValGluThrLeuArgAlaGlyAspPr	
4751	TGCCGACCCGGAGTCGGTGCTCGGTTTCGCTGGTGGACGCCAGCGCTGGCA	4800
	oAlaAspProGluSerValLeuGlySerLeuValAspAlaSerAlaGlyT	
4801	CGCGGATCAAAGCGTTGATCGATGATGCCGTGGCCAAGGGCGCGCGCCTG	4850
	hrArgIleLysAlaLeuIleAspAspAlaValAlaLysGlyAlaArgLeu	
4851	GTAATCGGCGGGCAACTGGAGGGCAGCATCTTGCAGCCGACCCTGCTCGA	4900
	ValIleGlyGlyGlnLeuGluGlySerIleLeuGlnProThrLeuLeuAs	
4901	CGGTGTCGACGCGAGCATGCGTTTGTACCGGAAGAGTCCTTCGGCCCCGG	4950
	pGlyValAspAlaSerMetArgLeuTyrArgGluGluSerPheGlyProV	
4951	TGGCGGTGGTGCTGCGCGGCGAGGGCGAAGAAGCGCTGTTGCAACTGGCC	5000
	alAlaValValLeuArgGlyGluGlyGluGluAlaLeuLeuGlnLeuAla	
5001	AACGACTCCGAGTTCGGTTTGTGCGCGGCGATTTTCAGTCGTGACACCGG	5050
	AsnAspSerGluPheGlyLeuSerAlaAlaIlePheSerArgAspThrGl	
5051	CCGTGCCCTGGCCCTGGCCCAGCGGGTCGAATCGGGCATCTGCCACATCA	5100
	yArgAlaLeuAlaLeuAlaGlnArgValGluSerGlyIleCysHisIleA	
5101	ACGGCCCCGACCGTGACGACGAAGCGCAAATGCCTTTTGGCGGGGTCAAG	5150
	snGlyProThrValHisAspGluAlaGlnMetProPheGlyGlyValLys	
5151	TCCAGCGGCTACGGCAGTTTGGCGGCAAGGCATCGATTGAGCATTTTCAC	5200
	SerSerGlyTyrGlySerPheGlyGlyLysAlaSerIleGluHisPheTh	
5201	TCAGTTGCGCTGGGTCACCCTCCAGAATGGTCCACGGCACTATCCGATCT	5250
	rGlnLeuArgTrpValThrLeuGlnAsnGlyProArgHisTyrProIleE	
5251	GA 5252	
	nd	

Figure 12 (Part 5 of 5)

17/27

Nucleotide sequence of pFI901 (1.8Kb EcoRI/PstI fragment ex pFI973)

1 GAATTCGGGA TCTGGGCTGC CAACCAGTTG GAAGAAAAGA TTCTCGAAGT  
 51 CGGTGTCGAC AACGTCGGCG CCTTCATTGC CGAGCCGATC CAGGGCGCCG  
 101 GCGGCGTGAT CGTGCCGCCA GAAAGCTACT GGCCGCGCAT CAAGGAAATC  
 151 CTCGCCAAGT ACGACATCCT GTTCGTCGCC GATGAAGTGA TTTGCGGTTT  
 201 CGGCCGTACC GCGAGTGGT TCGGCAGCGA TTTCTACGAC CTCAAGCCCC  
 251 ACATGATGAC CATCGCCAAG GGCCTGACTT CCGGCTACAT CCCGATGGGT  
 301 GGTCTGATCG TGCGCGATTC GGTGGTCGAA GTGCTGAACG AAGGCGGCGA  
 351 TTTCAACCAC GGATTACCT ACTCCGGTCA CCCGGTAGCG GCGGCTGTTG  
 401 CCCTGGAAAA CATCCGCATC ATGCGCGAAG AGAAGATTAT CGAGCGCGTC  
 451 CAGGAAGAAA CGGCACCGTA TTTGCAAAAAG CGTCTGCGTG AACTCAACGA  
 501 TCATCCATTG GTGGGTGAAG TTCGCGGGGT AGGGTTGCTG GCGCTATCG  
 551 AACTGGTTCA GGACAAAGCC ACGCGCAAAC GTTACGAAGG CAAGGGCGTG  
 601 GGCATGATCT GCCGGCAGTT CTGCTTCGAC AACGGGCTGA TCATGCGCGC  
 651 GGTTGGCGAC ACCATGATCA TCGCGCCGCC ACTGGTGATT ACCAAGGCGG  
 701 AAATCGATGA GCTGGTGAGC AAGGCACGCA AGTGCCTGGA CCTGACCCTG  
 751 AGTGTGTTGC AGGGCTAAGT GCTAGGCTCT GAGCGGGAGT TGTATGAACT  
 801 TTCGCTCAGA GCGGTCAGAA AGCTTGGCCT TTCCTTGAAA GACCGCCATG  
 851 GATGTTGCCA GACTAGCCAC CGTTCCAAAT GCCCGGGTTC GGCGCGGAAC  
 901 AGGTGGTTCA AAAAAGCAAA AATTTGGAGC ATTACGCATG AAGGCACTCG  
 951 GTAAAAAGCT CGCCGGCAAG AACTCCTTG CCATGTCCCT GATGGGCATC  
 1001 ATGGCGGGCG CGGTTCAGGC AGATGACAAA GTCTTGACAG TGTACAACTG  
 1051 GTCCGATTAC ATCGCGCCCG ACACCATCAA GAAGTTTGAA GACGAGTCGG  
 1101 GCATCAAGGT GGTCTACGAC GTCTTCGACA GTAACGAAAC CCTCGAAGCC  
 1151 AAGTTGCTGG CCGGCAAGTC CGGTTACGAC ATCGTGGTGC CTTCAACAA  
 1201 CTTCTGGCC AAGCAGATCA AGGCCGGCGT CTACCAGAAG CTGGACAAGT  
 1251 CCAAGCTGCC GAACTGGAAG AACCTGAACA CCGATCTGCT CAAGGCCGTT  
 1301 TCGGTCAGCG ACCCTGGTAA CGAGCACGCC TTCCCGTACA TGTGGGGCTC

**Figure 13 (Part 1 of 2)**

18/27

1351 GATCGGCATC GGCTTCAACG CCGAGAAGGT CAAGGCCGCG CTGGGTCCGG  
1401 ATGCACCGAC CAATTCCTGG GACCTGATCT TCAAACCGGA AAACGCCGCC  
1451 AAGCTGAAAT CCTGTGGCAT CAGCGTGCTG GATTCGCCAA CCGAGATGAT  
1501 TCCGGTGGCC CTGCACTACC TGGGCTACCC GACCGACAGC CAGGACAAGA  
1551 AACAACTGGC CGAGGCCGAG GCACTGTTCC TCAAAGTTCG TCCTTCGATC  
1601 GGTTACTTCC ACTCCTCCAA GTACATTTCC GACCTGGCCA ACGGCAACAT  
1651 CTGCGTGGCG ATCGGCTACT CGGGTGACAT CTATCAGGCC AAGACTCGCG  
1701 CCGCCGAAGC CGGTGACAAG GTCAAGGTCA GCTACAACAT TCCCAAAGAA  
1751 GGTGCAGGCA GCTTCTACGA CATGGTCGCC ATCCCTAAAG ATGCCGAAAA  
1801 CGTCGAAGGC GCCTACAAGT TCATGACCTT CCTGCAG

Figure 13 (Part 2 of 2)

19/27

Nucleotide sequence pFI911 (850bp EcoRI/PstI fragment ex pFI973)

```
1  CTGCAGACCT TCTGCCAGGC GCACCGGCTC ACGCAGGGTT TTGACTTCCT
51  GGATCATCAG GCGCTGGTTG CGTTTGACCG ACTGGCCAAT CATCAGGCCA
101 AACGCATTGG AGCCCAGGTC GATAGCGGCG AATAGCGATG CGTCTTCTTT
151 CACGTGAGGA ACTCCTGGCA ACTTCGTCCG CCGAGGGCAA AAAACCGGTT
201 TTGCCGATCC TGCACGGGGT AGATGACATC AGGATGACAT TGGAAATTTT
251 TCTGACAGAC GTTTCGTCAC CAGAACGTCA CAGTCGCGGG GCTAGCATCG
301 GGGCTTCCAA TCGGGTCGGG AGCCTTGAAC ATGCTGTAA CCAACGACAC
351 CCTGATGCAT CGCATCCACC GCGAGTTGCT CGACCACAGT GACGAAGAGC
401 TGGAAC TGGA GTTGCTGGAA GACGATCACG ACCTGGCTTC GCTGTTCCGG
451 GATCAACCGG GCGATACCCC GGCCAAGGCC GAGCGCCGTC GTTACTTCAG
501 CGAGTTGTTT CGTTTGCAGG GCGAGTTGGT CAAGTTGCAA AGCTGGGTGG
551 TGAAGACCGG GCACAAGGTG GTGATTCTGT TCGAAGGCCG CGATGCCGCT
601 GGCAAAGGGG GCGTGATCAA GCGCATCACC CAGCGTCTTA ATCCACGGGT
651 CTGCCGGGTC GCGGCGCTTC CCGCGCCGAG TGACCGCGAG CGCACCCAGT
701 GGTATTTCCA GCGTTATGTC TCGCACCTGC CCGCCGCCGG CGAGATCGTC
751 CTGTTTCGACC GCAGCTGGTA CAACCGCGCC GGTGTCGAGC AGGTGATGGG
801 CTTTTGCAAC GAGGAACAGT ACGAAGAATT TTTCCGCAGC GTGCCGGAAT
851 TC
```

Figure 14



20/27

Nucleotide sequence pFI912 (958bp EcoRI/PstI fragment ex pFI793)

```
1  CTGCAGGGCC TGGGGCATGC CGAGTCGGCG TCGCAGAACG CCTCTGCCTA
51  TGCCTGGAA  CGCAAGCAA  TGCCTGCGCC CGCTCGCCCG GTCGGAGTCG
101 AAGCCGAAGT GGCCGACCCC ATTCATTTTC ATCCGGCCAT GCGCCGGGTG
151 TTGCTGGAAC TGAGGGCCTA TGCCGAGGGC ATGCGTGGCG TCGGTTACTG
201 GGCGGCGCAT TTGTTGGATC AGTCCGAGCA GGCCGAGGAT CTGCCCCTC
251 GTCAGCGCGC CTTGCAACTG GCGGAGCTGC TGACGCCGGT GATCAAGGCG
301 TTCTTCACCG AGCAGGGTTT TCGCCTGGCC AGCAACGCCT TGCAGGTGTT
351 CGGTGGCTAC GGCTACGTCA GCGAGTTCGC CATCGAACAG ACCCTGCGCG
401 ACAGCCGGAT CGCGATGATT TACGAGGGCA GCAACGAAAT CCAGGCCAAT
451 GACCTGCTGC TGCGCAAAGT GCTGGGGGAT GAAGGTCGCG CCTTTGGCCA
501 ACTGTTGGCG GTCATGCGCG AAGAGGCCGA ACTGGCCTGT AACGACACCC
551 GCTTTGGCGC TGAGCTGGTG CAGCTGTGCG ACAAACTCGA GACAGTGCAA
601 CTTGAGATAG GGGACCTCGC CGTCACGGAG CGCGAATACC CGTATCGAGC
651 CGCTGGCGAT TTCCTGCGCC TGTGTGGCGT GCGCTGTTG GGGTTTTCTT
701 GGGCGAGAGC GGCACGGGTG TCTCGCCTGT TACCTGACAG CGATCCACTG
751 CGTCCCAACA AACTGGAAAC CGCGCGTTTC TTCTTTGCCT ACCTGCTGCC
801 AGAAGCCGAT CAACGCCTCG CAGCCATTCG GGCGGCGAGA GCGCCGTTGC
851 CGTTTTTGAT CTGAAAAAAC GCCCGCCAGG CCCAATGTGG CTCGCTCCCA
901 CAAACAGCGC GAACCACATC GAGCCACCGC CGCCACGCCA GTTGACAGG
951 CCGAATTC
```

Figure 15

21/27

Nucleotide sequence pFI913 (959bp EcoRI/PstI fragment ex pFI793)

1 CTGCAGGCTT GCCATATCAG TGGCGACAGC TTCGTCCGCG CTCCAGGCGC  
51 AAGGGCCAAC GACCTGCCGA CGGTGCCGAA TAGGCTGTCTG GCGTCCGTTA  
101 TTCTGGACGC ACCGCAAAAA CTGTTATTTA CCCGGTCTTC TTCCACTGTA  
151 GAACCTTTTC ACTATAGCGG CCCTGCGTGT TCTGCGGGAG CTGCTCATGA  
201 TTCTGCACGC GATTCCACTT CCAGCCCGTT GCCGCGCCGT GCTGTTGCGG  
251 TTTCTGCACG CACGGCTTTT GCATCAGGCT TGCACAGCCA GCCACAAGGG  
301 CAGGTAAGCT CTAGCTCGCA CGTCCTGGGC GTCTCCCAGG TCTGCCAACG  
351 CGACGCGGAC GCGTCAAACA ACGCCCGGCC CCTAATGAAG CCGGGACACT  
401 CAGCCCAGAG GCATTTATGA GTAACAACCT CGACCAGCTC ACCGATTGGT  
451 TGAAAGACCA CAAGATCACA GAAGTCGAAT GCATGATTGG CCACTTGACC  
501 GGGATCACCC GCGGCAAGAT CTCGCCAACC AACAAGTTCA TTGCCGAAAA  
551 AGGCATGCGC CTGCCCAGAG GTGTGCTGTT GCAGACAGTG ACGGGCGACT  
601 ATGTCTGAAGA CGACATCTAT TACGAACTGC TCGACCCGGC CGACATCGAC  
651 ATGATCTGCC GCCCCGACCA GAACGCGGTG TTCCTCGTGC CATGGGCCAT  
701 CGAGCCGACC GCGCAGGTGA TTCACGACAC CTACGACAAG CAGGGCAACC  
751 CGATCGAGCT GTCGCCACGC AACGTCCTCA AGAAAGTCCT CAACTCTAT  
801 TCCGACAAGG GCTGGCAGCC GATCGTGGCG CCGGAAATGG AGTTCTACCT  
851 GACCAAGCGC AGTGACGACC CGGATTACCC ATTGCAACCG CCGGTTGGCC  
901 GTTCCGGACG TCCGGAAATC GGTCGCCAAT CGTTCTCTAT CGAAGCGGCC  
951 AACGAATTC

Figure 16

22/27


Outward reading PCR primers

Figure 17




Figure 18

24/27

Nucleotide sequence merged contigs pFI913/PCR product/pFI901(4259bp)

1 CTGCAGGCTT GCCATATCAG TGGCGACAGC TTCGTCCGCG CTCCAGGCGC  
 51 AAGGGCCAAC GACCTGCCGA CGGTGCCGAA TAGGCTGTCT GCGTCCGTTA  
 101 TTCTGGACGC ACCGCAAAAA CTGTTATTTA CCCGGTCTTC TTCCACTGTA  
 151 GAACCTTTTC ACTATAGCGG CCCTGCGTGT TCTGCGGGAG CTGCTCATGA  
 201 TTCTGCACGC GATTCCACTT CCAGCCCGTT GCCGCGCCGT GCTGTTGCGG  
 251 TTTCTGCACG CACGGCTTTT GCATCAGGCT TGCACAGCCA GCCACAAGGG  
 301 CAGGTAAGCT CTAGCTCGCA CGTCCTGGGC GTCTCCCAGG TCTGCCAACG  
 351 CGACGCGGAC GCGTCAAACA ACGCCCGGCC CCTAATGAAG CCGGGACAET  
 401 CAGCCCAGAG GCATTTATGA GTAACAACCT CGACCAGCTC ACCGATTGGT  
 451 TGAAAGACCA CAAGATCACA GAAGTCGAAT GCATGATTGG CGACTTGACC  
 501 GGGATCACCC GCGGCAAGAT CTCGCCAACC AACAAGTTCA TTGCCGAAAA  
 551 AGGCATGCGC CTGCCCAGAG GTGTGCTGTT GCAGACAGTG ACGGGCGACT  
 601 ATGTCGAAGA CGACATCTAT TACGAACTGC TCGACCCGGC CGACATCGAC  
 651 ATGATCTGCC GCCCCGACCA GAACGCGGTG TTCCTCGTGC CATGGGCCAT  
 701 CGAGCCGACC GCGCAGGTGA TTCACGACAC CTACGACAAG CAGGGCAACC  
 751 CGATCGAGCT GTCGCCACGC AACGTCCTCA AGAAAGTCCT CAAACTCTAT  
 801 TCCGACAAGG GCTGGCAGCC GATCGTGGCG CCGGAAATGG AGTTCTACCT  
 851 GACCAAGCGC AGTGACGACC CGGATTACCC ATTGCAACCG CCGGTTGGCC  
 901 GTTCCGACG TCCGGAAATC GGTGCGCAAT CGTTCTCTAT CGAAGCGGCC  
 951 AACGAATTCG ACCCGCTGTT CGAAGACGTC TACGACTGGT GCGAACTGCA  
 1001 GGAGCTGGAT CTCGATACGC TGATCCACGA AGACGGCACG GCGCAGATGG  
 1051 AAATCAACTT CCGTCACGGC GACGCGCTGT CCCTGGCCGA CCAGATCCTG  
 1101 GTGTTCAAGC GCACCATGCG CGAGGCCGCG CTCAAGCACA ACGTGGCCGC  
 1151 CACGTTTCATG GCCAAGCCGA TGACCGGCGA GCCTGGCAGC GCCATGCACC  
 1201 TGCACCAGAG CATCATCGAT ATCGAGACCG GCAAGAACGT CTTCTCCAAT  
 1251 GAAGACGGGA GCATGAGCCA GTTGTTCTCT AACCACATCG GCGGCCTGCA  
 1301 GAAATTCATC CCTGAACTGC TGCCGCTGTT CGCGCCCAAC GTCAACTCGT

**Figure 19 (Part 1 of 4)**  
**SUBSTITUTE SHEET (RULE 26)**

25/27

1351 TCCGCCGCTT CCTG~~C~~CGGAC ACTTCGGCGC CGGTGAACGT CGAGTGGGGC  
 1401 GAAGAAAACC GTACCGTGGG CCTGCGGGTG CCGGATGCCG GCCCTCAAAA  
 1451 CCGTCCGGTG GAAAACCGCC TGCCGGGTGC CGACGCCAAC CCGTACCTGG  
 1501 CGATTGCCGC GAGCCTGCTG TGCGGCTACA TCGGCATGGT CGAAGGTATC  
 1551 AACCCAAGCG CGCCTGTGGT GGGTCGTGGT TACGAGCGGC GCAACCTGCG  
 1601 TCTGCCGCTG ACCATCGAAG ACGCTCTGGA ACGCATGGAA AACAGCAAGA  
 1651 CCATCGAGAA ATACCTGGGT CACAACCTCA TCACTGGCTA CGTCGCGGTC  
 1701 AAGCGGGCCG AGCATGAAAA CTTCAAGCGC GTGATCAGCT CATGGGAACG  
 1751 GGAATTCCCTG TTGTTCCGGC TCTGACACGC CGGGTGCGGC CCTCAAAAGC  
 1801 CGCACTCCAA CCTCACTAGG AGAGCTTTAT GAGCAACAAC CCGCAAACCC  
 1851 GTGAATGGCA GAACCTGAGC GCCGAACACC ACCTGGCCCC CTTCACTGAC  
 1901 TTCAAGCAAT TGAAGGAAAA AGGCCCGCGC GTCATCACCA GCGCCAAGGG  
 1951 CGTTTACCTG TGGGACAGCG AAGGCAATCA GATCCTCGAC GGCATGGCCG  
 2001 GCCTGTGGTG CGTGGCCATC GGTACGGCC GCGACGAGTT GGCCGAGGCT  
 2051 GCCAGCAAGC AGATGCGCGA GTTGCCGTAC TACAACCTGT TTTTCCAGAC  
 2101 CGCTACCCCG CCCGTCCTCG AGCTGGCCAA GGCAATTTCC GATATCGCGC  
 2151 CAGCAGGCAT GAACCACGTG TTCTTCACCG GTTCCGGCTC CGAAGGCAAT  
 2201 GACACCATGC TGCGCATGGT TCGCCACTAC TGGGCGATCA AAGGTCAGCC  
 2251 AAACAAGAAA GTCATTATCA GCCGCAAGAA CGGCTACCAC GGTTCGACCG  
 2301 TGGCCGGCGC CAGCCTGGGC GGCATGACCT ACATGCACGA ACAGGGCGAC  
 2351 TTGCCGATCC CGGGCATCGT GCACATTCCG CAGCCGTAAT GGTTCGGTGA  
 2401 AGGCGGCGAC ATGACCCCGG AAGAATTCGG GATCTGGGCT GCCAACCAGT  
 2451 TGGAAGAAAA GATTCTCGAA GTCGGTGTG ACAACGTCGG CGCCTTCATT  
 2501 GCCGAGCCGA TCCAGGGCGC CGGCGGCGTG ATCGTGCCGC CAGAAAGCTA  
 2551 CTGGCCGCGC ATCAAGGAAA TCCTCGCCAA GTACGACATC CTGTTCTGTCG  
 2601 CCGATGAAGT GATTTGCGGT TTCGGCCGTA CCGGCGAGTG GTTCGGCAGC  
 2651 GATTTCTACG ACCTCAAGCC CGACATGATG ACCATCGCCA AGGGCCTGAC  
 2701 TTCCGGCTAC ATCCCGATGG GTGGTCTGAT CGTGCGCGAT TCGGTGGTCCG  
 2751 AAGTGCTGAA CGAAGGCGGC GATTTCAACC ACGGATTAC CTAATCCGGT

26/27

2801 CACCCGGTAG CGGEGGCTGT TGCCCTGGAA AACATCCGCA TCATGCGCGA  
2851 AGAGAAGATT ATCGAGCGCG TCCAGGAAGA AACGGCACCG TATTTGCAAA  
2901 AGCGTCTGCG TGAACTCAAC GATCATCCAT TGGTGGGTGA AGTTCGCGGG  
2951 GTAGGGTTGC TGGGCGCTAT CGAACTGGTT CAGGACAAAG CCACGCGCAA  
3001 ACGTTACGAA GGCAAGGGCG TGGGCATGAT CTGCCGGCAG TTCTGCTTCG  
3051 ACAACGGGCT GATCATGCGC GCGGTTGGCG ACACCATGAT CATCGCGCCG  
3101 CCACTGGTGA TTACCAAGGC GGAAATCGAT GAGCTGGTGA GCAAGGCACG  
3151 CAAGTGCCTG GACCTGACCC TGAGTGTGTT GCAGGGCTAA GTGCTAGGCT  
3201 CTGAGCGGGA GTTGTATGAA CTTTCGCTCA GAGCGGTCAG AAAGCTTGGC  
3251 CTTTCCTTGA AAGACCGCCA TGGATGTTGC CAGACTAGCC ACCGTTCCAA  
3301 ATGCCCCGGT TCGGCGCGGA ACAGGTGGTT CAAAAAAGCA AAAATTTGGA  
3351 GCATTACGCA TGAAGGCACT CGGTAAAAAG CTCGCCGGCA AGACACTCCT  
3401 TGCCATGTCC CTGATGGGCA TCATGGCGGG CGCGGTTTCA GCAGATGACA  
3451 AAGTCTTGCA CGTGTACAAC TGGTCCGATT ACATCGCGCC GGACACCATC  
3501 AAGAAGTTTG AAGACGAGTC GGGCATCAAG GTGGTCTACG ACGTCTTCGA  
3551 CAGTAACGAA ACCCTCGAAG CCAAGTTGCT GGCCGGCAAG TCCGGTTACG  
3601 ACATCGTGGT GCCTTCGAAC AACTTCCTGG CCAAGCAGAT CAAGGCCGGC  
3651 GTCTACCAGA AGCTGGACAA GTCCAAGCTG CCGAACTGGA AGAACCTGAA  
3701 CACCGATCTG CTCAAGGCCG TTTCGGTCA GACCCCTGGT AACGAGCACG  
3751 CCTTCCCGTA CATGTGGGGC TCGATCGGCA TCGGCTTCAA CGCCGAGAAG  
3801 GTCAAGGCCG CGCTGGGTCC GGATGCACCG ACCAATTCCT GGGACCTGAT  
3851 CTTCAAACCG GAAAACGCCG CCAAGCTGAA ATCCTGTGGC ATCAGCGTGC  
3901 TGGATTCGCC AACCGAGATG ATTCCGGTGG CCCTGCACTA CCTGGGCTAC  
3951 CCGACCGACA GCCAGGACAA GAAACAACCTG GCCGAGGCCG AGGCACTGTT  
4001 CCTCAAAGTT CGTCCTTCGA TCGGTACTT CCACTCCTCC AAGTACATTT  
4051 CCGACCTGGC CAACGGCAAC ATCTGCGTGG CGATCGGCTA CTCGGGTGAC  
4101 ATCTATCAGG CCAAGACTCG CGCCGCCGAA GCCGGTGACA AGGTCAAGGT  
4151 CAGCTACAAC ATTCCCAAAG AAGGTGCAGG CAGCTTCTAC GACATGGTCG  
4201 CCATCCCTAA AGATGCCGAA AACGTGCAAG GCGCCTACAA GTTCATGACC

WO 97/35999

PCT/GB97/00809

27/27

4251 TTCCTGCAG

Figure 19 (Part 4 of 4)

SUBSTITUTE SHEET (RULE 26)



